




SEMI-ANNUAL
MANAGEMENT

REPORT
OF THE

JGL
GROUP



2021

JADRAN – GALENSKI LABORATORIJ d.d. (“JGL”, “Company” or “Parent Company”) accepts responsibility for the content of this semi-annual JGL Group Management Report.

Given the belief and all discoveries and information available to JGL, information in this report represents a complete and truthful presentation of assets and liabilities, losses and gains and the financial position of the JGL Group, and to the best knowledge of the Company, no fact has been left out that can affect the completeness and truthfulness of this report.


Numbers in the report are rounded up in some places, so the numbers shown for the same type of information can differ and the sums may not be arithmetic aggregates. In this document, “EUR” stands for the euro, “USD” for the American dollar, and “HRK” or “kuna” for the Croatian kuna.

Reference to the “previous period” relates to the period from 1 January 2020 to 30 June 2020, while the “current period” relates to the period from 1 January 2021 to 30 June 2021.

Rijeka, August 2021


CONTENTS

OVERVIEW OF THE GENERAL POSITION	5
GENERAL DATA	11
IMPORTANT BUSINESS EVENTS	15
MEMBERS' REPORTING YEAR	21
SALES RESULTS	25
RISKS, EXPOSURE AND PROTECTION	33
FUTURE COMPANY DEVELOPMENT	38
JGL GROUP FINANCIAL STATEMENTS	39
JGL D.D. FINANCIAL STATEMENTS	55
STATEMENT OF RESPONSIBILITY OF THE CEO	70



OVERVIEW OF THE

GENERAL POSITION



SIGNIFICANT FINANCIAL INDICATORS

	JGL GRUPA	JGL PHARMA
Total revenue (in HRK million)	417	320
Operating revenue MAT (in HRK million)	970	772
EBITDA MAT (in HRK million)	125	114
EBITDA MAT margin	12.9%	14.8%
Profit before tax (in HRK million)	7.4	3.2
Indebtedness factor (Net debt / EBITDA MAT)	3.2	3.3

SIGNIFICANT BUSINESS EVENTS

INTEGRA 2020

15 new B2B contracts

RINO SPREJ ("RINO SPRAY")

The establishment of the company
JGL PPH d.o.o.

Clindamycin + Benzoyl Peroxide
launched in UK

Overview of the results of the
JGL Group, JGL Pharma and
JGL d.d. on 30 June 2020 and
30 June 2021

in HRK million

	JGL GROUP		JGL PHARMA		JGL d.d.		
	30/06/2020	30/06/2021	30/06/2020	30/06/2021	30/06/2020	30/06/2021	30/06/2021*
Total revenue	460.7	417.1	362.3	319.9	284.1	294.5	229.6
Operating revenue	453.3	412	354.9	314.8	276.5	289.5	224.6
EBITDA	71.1	33.2	62.9	26.1	76	95.3	30.3
Profit before tax	28	7.4	22.5	3.2	38.6	74.8	9.8
EBITDA MAT¹	161.4	124.8	149	114.1	138.9	146.1	81.1
Operating revenue, MAT	971.1	970.1	780.2	771.8	595	598.6	533.6
EBITDA MAT margin	16.62%	12.87%	19.10%	14.79%	23.34%	24.41%	15.20%
Net debt	349.2	398.4	332.8	378.2	334.9	381.7	381.7
Net debt / EBITDA (MAT)	2.16	3.19	2.23	3.31	2.41	2.61	4.71
Net debt / capital	0.51	0.59	0.50	0.58	0.48	0.51	0.51
Debt ratio	0.47	0.47	0.45	0.45	0.42	0.41	0.41
Quick liquidity ratio	1.48	1.28	1.68	1.41	1.99	1.66	1.66
Number of employees	1,041	1,103	865	930	605	667	667

¹ Moving annual total (MAT)

* normalised – adjusted for the sale of rights arising from the contract with Polpharma, transaction from JGL d.d. and JGL PPH d.o.o.

The first half of 2021 was marked by degraded mode of operation due to the COVID-19 pandemic that resulted in a sharp decline in demand and a decrease in sales of about 9% compared to the previous period (the first half of 2020), as well as the decrease in the operating profit and EBITDA margin. If we look at the data from the JGL Group that reflect the period of 12 months, the operating revenue MAT and EBITDA MAT, it is an amount of HRK 970 million in revenue (HRK 971 million in 2020) and around HRK 125 million in operating profit (HRK 161.4 million in 2020), and the EBITDA margin of 12.9% (16.6% in 2020), which is a decrease compared to the previous period, but given the pandemic business conditions, the achieved result is satisfactory. At the level of pharmaceutical business (JGL Pharma), the EBITDA margin for the last 12 months is 14.8% (19.1% in 2020), and the operating profit is HRK 114 million (HRK 149 million in 2020).

The biggest market of JGL Pharma is still Russia, with 37% share in net sales, followed by Croatia (22%), Business-to-Business operations (12%) and Ukraine (9%). If we take a look at the segments, the Aqua Maris program accounts for the largest share in net sales (27%), followed by B2B (11%), Acnecutan (9%) and Meralys (7%).

In the context of financial statements of the parent company JGL d.d., it is important to mention the establishment of the company JGL PPH d.o.o., a special purpose vehicle (SPV) established for easier imple-

mentation and monitoring of a specific business segment involving the foreign partner Polfa Warszawa S.A. After the establishment, the rights of the company JGL PPH d.o.o. were used for the purpose of recapitalisation in the amount of HRK 65 million, which resulted in an increase in other operating revenue and the investment in shares of companies within the Group. So the statement of P&L and Balance Sheet of the Parent Company should be observed as normalised, less this transaction.

By entering the new investment cycle in project INTEGRA 2020, the net debt increased, and consequently also the net debt/EBITDA of the Group, i.e. the parent company JGL d.d. It is a new long-term HBOR loan used to finance one part of the project (HRK 280 million), while the other part is self-financed (HRK 90 million). The debt for new HBOR loan on 30 June 2021 amounts to HRK 64 million.

The balance sheet shows significant changes in current assets, more specifically, the decrease in trade receivables due to decreased sales, and the decrease in current financial assets (investment in investment funds). Current liabilities under loans and leasing are reduced by regular payment of the existing HBOR loan and leasing, while non-current liabilities towards banks have increased (INTEGRA 2020 investment).

Despite the reducing income due to the pandemic and the effect of the new investment, the JGL Group has solid financial indicators.

At the end of the first half of the year, the indebtedness of the JGL Group (net debt / EBITDA MAT) is 3.19, while the indebtedness factor is stable at 0.47, and the liquidity ratio at 1.28.

Statement of profit or loss of the JGL Group, JGL Pharma
and JGL d.d. (in HRK) on 30 June 2020 and 2021


in HRK thousand

	JGL GROUP			JGL PHARMA			JGL D.D.		
	30/06/2020	30/06/2021	Index	30/06/2020	30/06/2021	Index	30/06/2020	30/06/2021	Index
Operating revenue	453,296	411,975	90.88	354,905	314,778	88.69	276,487	289,532	104.72
Sales revenue	441,861	402,293	91.05	349,498	311,612	89.16	272,363	222,783	81.80
Other revenue	11,435	9,682	84.67	5,407	3,166	58.54	4,124	66,749	1618.45
Operating expenses	406,169	403,450	99.33	313,613	310,773	99.09	219,662	214,097	97.47
Change in inventory value	-17,996	-30,357	168.69	-18,098	-31,112	171.90	-17,726	-30,870	174.15
Material costs	97,916	95,405	97.44	95,209	92,285	96.93	93,849	89,875	95.77
Personnel costs	85,124	86,865	102.05	73,262	74,844	102.16	47,071	50,757	107.83
Depreciation	24,002	24,663	102.75	21,602	22,122	102.41	19,133	19,836	103.67
Other costs	217,123	226,874	104.49	141,638	152,634	107.76	77,335	84,499	109.27
Finance revenue	7,367	5,148	69.88	7,366	5,146	69.86	7,630	5,004	65.59
Finance expenses	26,508	6,247	23.57	26,165	5,945	22.72	25,887	5,661	21.87
Total revenue	460,663	417,123	90.55	362,271	319,924	88.31	284,117	294,536	103.67
Total expenses	432,677	409,697	94.69	339,778	316,718	93.21	245,549	219,758	89.50
Profit before tax	27,986	7,426	26.53	22,493	3,206	14.25	38,568	74,778	193.88

Balance sheet of the JGL Group, JGL Pharma
and JGL d.d. (in HRK) on 31 December 2020
and 30 June 2021

in HRK thousand

	JGL GROUP			JGL PHARMA			JGL D.D.		
	31/12/2020	30/06/2021	Index	31/12/2020	30/06/2021	Index	31/12/2020	30/06/2021	Index
Assets	1,326,981	1,342,687	101.18	1,236,785	1,257,846	101.70	1,208,838	1,301,473	107.66
Non-current assets	697,894	762,820	109.30	669,083	734,615	109.79	675,386	802,363	118.80
Current assets	623,501	575,460	92.29	563,419	519,767	92.25	530,442	497,155	93.72
Inventory	216,054	271,325	125.58	192,309	246,595	128.23	170,710	222,865	130.55
Trade receivables and receivables from affiliated companies	311,705	217,807	69.88	285,299	192,732	67.55	297,964	230,578	77.38
Current financial assets	19,807	289	1.46	19,743	149	0.75	21,970	5,244	23.87
Cash at bank and in hand	32,591	27,488	84.34	24,316	23,288	95.77	11,878	6,665	56.11
Other receivables	43,344	58,551	135.08	41,752	57,003	136.53	27,920	31,803	113.91
Prepaid expenses and accrued revenue	5,586	4,407	78.89	4,283	3,464	80.87	3,010	1,955	64.94
Liabilities	1,326,981	1,342,687	101.18	1,236,785	1,257,846	101.70	1,208,838	1,301,473	107.66
Capital and reserves	681,885	677,915	99.42	662,730	654,539	98.76	690,829	754,935	109.28
Non-current liabilities	348,910	395,549	113.37	333,595	378,873	113.57	328,623	374,382	113.92
Non-current provisions	3,429	3,429	100.00	2,816	2,816	100.00	2,816	2,816	100
Liabilities for leasing and banks	213,564	259,964	121.73	202,468	247,507	122.24	197,522	243,065	123.06
Bond liabilities	128,285	128,501	100.17	128,285	128,501	100.17	128,285	128,501	100.17
Deferred tax liability	3632	3655	100.65	26	49	190.26	0	0	0
Current liabilities	274,991	237,217	86.26	220,275	193,437	87.82	180,973	165,542	91.47
Suppliers	173,925	163,023	93.73	137,104	133,995	97.73	103,535	119,442	115.36
Financial liabilities	4,000	6,000	150.00	4,000	6,000	150.00	4,000	6,000	150
Liabilities towards banks and leasing	59,700	37,737	63.21	46,067	25,635	55.65	42,952	22,080	51.41
Other current liabilities	37,366	30,457	81.51	33,104	27,807	83.99	30,486	18,020	59.11
Accrued expenses, deferred revenue	21,195	32,006	151.01	20,185	30,997	153.56	8,413	6,614	78.62



GENERAL DATA

NAME AND HEADQUARTERS

JADRAN – GALENSKI LABORATORIJ d.d.

joint stock company founded in Croatia

Seat address: Svilno 20, 51000 Rijeka, Croatia

MB: 03715957

Personal Identification No. (OIB): 20950636972

JGL GROUP MEMBERS

Consolidated financial statements of the JGL Group include financial statements of the parent company JGL d.d. and entities controlled by the Parent Company and subsidiaries specified below. Control exists if the Parent Company is able to manage financial and business policies of an entity so as to benefit from its activities.

Consolidated financial statements of the JGL Group include financial statements of the following companies:

Parent Company

- *JGL d.d. Rijeka*

Subsidiaries

- *JADRAN LLC Moskva*
- *Adrialab d.o.o. Rijeka*
- *JGL d.o.o. Beograd – Sopot*
- *Farmis d.o.o. Sarajevo*
- *Jadran – Galenski laboratorij d.o.o. Ljubljana*
- *Pablo d.o.o. Zagreb*
- *Pablo HI Rijeka*
- *JGL PPH d.o.o. Rijeka*
- *JGL North America LLC, New York, USA*

Entity under significant influence by the Parent Company

- *Galena d.o.o. Rijeka*

The term “JGL Pharma” (core business of the JGL Group) excludes PABLO d.o.o. Zagreb, Ljekarna Pablo Health Institution Rijeka, and Adrialab d.o.o. Rijeka.

ACCOUNTING POLICIES

During the preparation of financial statements for the semi-annual reporting period, as well as in the last annual reports, there was no change in the application of accounting policies.

OFF-BALANCE SHEET RECORDS

Financial liabilities of the Group that are not included in the balance sheet and that are monitored through off-balance sheet records are liabilities towards given guarantees and approved credit lines with banks. In the off-balance sheet records, this is presented as follows:

in HRK	31/12/2020	30/06/2021
Credit lines with banks	59,265,666	76,166,818
Issued guarantees	2,019,058	7,843,216
Received guarantees	4,298,526	28,724,726
Contracted loan restructuring	1,086,411	1,700,830
Total	66,669,661	114,435,590

The most significant change is the one in credit lines with banks that have been increased for the needs of regular business operations. Issued guarantees have also been increased for the purpose of ensuring advance in the RINO SPREJ (“RINO SPRAY”) project, and there was an increase in received guarantees that are the result of the INTEGRA 2020 project realisation.


TRANSACTIONS RELATING TO OWN SHARES


At the beginning of 2021, the Company had 76,957 own shares. By 30 June 2021, JGL repurchased 100 and allocated 3,298 own shares, so the number of own shares in the portfolio on 30 June 2021 was 73,759. The share capital of the Company is divided into 1,205,600 shares, 1,131,841 of which are shares with voting rights, while those remaining are own shares.

Ownership structure of JGL d.d.
on 30 June 2021

Owner	number of shares	% in capital	% in capital with voting rights
Ivo Usmiani	372,174	30.87%	32.88%
Small shareholders	350,992	29.11%	31.01%
Zdravko Saršon	240,496	19.95%	21.25%
Own shares	73,759	6.12%	
Eva Usmiani Capobianco	31,082	2.58%	2.75%
Marina Pulišić	29,296	2.43%	2.59%
Grozdana Božić	29,262	2.43%	2.59%
Vesna Črnjarić	24,512	2.03%	2.17%
Đurđica Miletović Forempoher	19,800	1.64%	1.75%
Sanja Vujić Šmaguc	19,627	1.63%	1.73%
Majid Hejja	14,600	1.21%	1.29%
Total	1,205,600	100.00%	100.00%

Source: JGL





IMPORTANT BUSINESS EVENTS

INTEGRA 2020 PROJECT

The ongoing project INTEGRA 2020 is an investment in the expansion of production capacities, equipment of the development laboratory, construction of a new pilot facility, refurbishment of the office space and the construction of a logistics centre.

It is an investment of HRK 373 million and it includes three areas – research and development, commercial production, and a logistics centre.

The investment is partially self-financed and partially financed by a long-term loan of the Croatian Bank for Reconstruction and Development in the amount of HRK 280 million. The project started at the end of 2019 with the aim of integrating development, production and storage capacities, which will create the technological preconditions for the future growth of the company. Integra 2020 includes three areas – research and development, commercial production, and a logistics centre.

From the beginning of the project to 30 June 2021, approximately 30% of the project was realised, and HRK 65 million of the loan was spent. The project is realised according to the planned schedule and it should be completed by 30 June 2022.





HBOR representatives with company leaders visiting the construction site in Kukuljanovo in May 2021



INVESTMENTS

During the first half of 2021, the JGL Group invested a total of HRK 72,326,453 in non-current assets. Investments in intangible assets amount to HRK 13,968,315, and are aimed at computer programs, acquisition of licences, registrations of own products, investments in non-owned assets and in the development of a web-store. JGL Group investments in tangible assets amount to HRK 58,358,138 and are primarily aimed at the improvement of functions of buildings owned by the Company, construction of new buildings, and at the procurement of production, IT, and transport equipment, as well as furniture, i.e. other tangible assets.

During the first half of 2021, the company JGL d.d. invested a total of HRK 69,405,950 in non-current assets. Investments in intangible assets amount to HRK 13,752,834, of which HRK 3,119,061 relates to investments in computer programs, HRK 359,553 to the acquisition of licences, HRK 912,073 to the registration of own products, HRK 9,316,347 to investments in development projects, and HRK 45,800 to investments in non-owned assets. Investments in tangible assets amount to HRK 55,653,116. The amount of HRK 21,618,658 relates to the improvement of functions of buildings owned by the Company and the construction of new buildings, while additional HRK 34,034,458 was invested in the procurement of production, IT, and transport equipment, as well as furniture and other tangible assets.

RINO SPREJ (“RINO SPRAY”) PROJECT

On 2 February 2021, the Ministry of Economy and Sustainable Development, Croatian Agency for SMEs, Innovations and Investments, and the company JGL d.d. as the beneficiary signed a Grant Agreement for the Project K.K.01.2.1.02.0111 – the development of a new product RINO SPREJ (projects financed by EU funds in the financial period 2014-2020).

The project has three implementation periods with the following deadlines:

- industrial research (17/08/2020 – 17/08/2023)
- experimental development (17/05/2022 – 17/08/2023)
- feasibility study (17/01/2021 – 17/08/2023)

Pursuant to Art. 3, paragraph 3.3 of the mentioned Agreement, the beneficiary is awarded a grant in the amount of HRK 13,870,898.97, which is the highest possible amount of co-financing of the total determined values of eligible Project expenditures.



PROJEKT JE SUFINANCIJIRALA EUROPSKA UNIJA IZ EUROPSKOG FONDA ZA REGIONALNI RAZVOJ



THE ESTABLISHMENT OF A NEW COMPANY AS PART OF A STRATEGIC PARTNERSHIP

Pursuant to the decision of the Commercial Court in Zagreb of 15 February 2021, the company JGL PPH d.o.o. was established as a new member of the Group, 100% owned by JGL d.d. The company JGL PPH d.o.o. was established for the purposes of future operations pursuant to the Strategic Partnership Agreement concluded with pharmaceutical company Polfa Warszawa S.A. from Poland, as a Special Purpose Vehicle (SPV) for the implementation and monitoring of a specific business segment involving the foreign partner. Such a common practice of establishing a special purpose vehicle will enable better monitoring of operations through a separate business entity, and thus provide better insight into the control and records of business events related to the strategic partnership agreement.

By establishing a special purpose vehicle, the rights and obligations under the Strategic Partnership Agreement with the pharmaceutical company Polfa Warszawa S.A. were transferred, and pursuant to the decision of the Commercial Court in Zagreb of 16 March 2021, the Company used the rights of JGL PPH d.o.o. for the purpose of recapitalisation in the amount of HRK 64,968,239.

This transaction resulted in an increase in investments in shares of companies within the Group, which is the result of the establishment and recapitalisation of JGL PPH d.o.o. by rights, i.e. receivables (transaction is not present in NT), and in an increase in other operating revenue within the Group.

Concerning the strategic partnership with Polpharma, several trial series, with the aim of creating validation series and initiating stability tests, were carried out



successfully. High level of expertise of JGL employees in the field of sterile technology was confirmed by signing the contract for 4 new projects relating to eye drops. Activities within new projects will begin at the end of 2021, and we expect the products to be marketed in 2024.

THE FIRST GENERIC PRODUCT IN THE EU


In the first half of 2021, the decentralised procedure (DCP) for Clindamycin + Benzoyl peroxide 10 mg/g + 50 mg/g of gel (Anti-acne gel) was successfully completed in eight EU countries. This is the first generic product in the EU, with a total of 18 new marketing authorisations (MA) in B2C business that have been ensured, and a total of 24 registration processes have been initiated in our own markets with the aim of continuous expansion of the portfolio in accordance with the goals of the Company. The product is marketed in Great Britain under a partner brand as the first generic parallel in that potent market.

PRODUCTS AND REGISTRATIONS

During the first half of 2021, nine registration activities were launched in several global markets (Malaysia, Saudi Arabia, Thailand and the UK), and marketing authorisations were obtained for a total of five products, including the aforementioned Clindamycin + Benzoyl peroxide 10 mg/g + 50 mg/g gel in the UK.

Preparations for the certification under the new EU regulation (MDR) that was supposed to enter into force on 26 May 2020 continued; however, due to the COVID-19 pandemic, the application of the Regulation (EU) 2017/745 on medical devices was postponed for one year, i.e. until 26 May 2021.

There are 29 products that were successfully marketed, 16 of which in nine markets of the B2C (Business-to-Consumer) business segment of JGL, which amounts to HRK 1,079,261.00 with approximately 30,000 packages sold. Other 13 products are related to ten B2B markets. The plan is to market another 46 new products in B2C and B2B segment by the end of 2021.



RESEARCH AND DEVELOPMENT ACTIVITIES

During the first half of 2021, the Research and Development Department was primarily focused on activities within the project relating to the development of own products. In the first six months, a total of 21 projects/topics were active in various stages of technological maturity, out of which 16 products were for the JGL portfolio, and five topics were related to technological transfers for partners.

CONTRACTS AND COOPERATIONS IN THE B2B SEGMENT


During the first six months of 2021, 15 new contracts were signed with partners, with a five-year revenue of HRK 113 million. Cooperation models are connected to contract manufacturing (eight contracts), licences (five contracts), and distribution (two contracts). It is expected that 12 new contracts will be finalised by the end of the year.

It is worth to mention the significant export in May 2021, when JGL delivered one million bottles of Na-zol under the brand Xylo Apteo of the Polish partner Synoptis. Furthermore, the first licensed Naftifine was marketed as part of B2B cooperation under the brand Videril in Czech Republic and Romania. In addition, the first licensed Xylo Ipra was marketed in Portugal, and cooperation in the markets of Italy, Spain, France and Belgium with existing partners was expanded. A number of activities related to strategic business development projects in Hungarian and Chinese markets are also under way.

The structure of net sales by B2B markets in the period from 1 January to 30 June 2021

EMPLOYEES

The total number of employees in the JGL Group on 30 June 2021 was 1,103, which is 60 employees more than on 30 June 2020. Among these, most employees work on the Croatian market, 694 (JGL d.d., Pablo HI, and Adrialab d.o.o.), while the Russian market employs 212 employees (Jadran LLC, JGL d.d., representative office in Russia). JGL Pharma employs a total of 930 employees, while the Parent Company employs 667 people.



	30/06/2020	30/06/2021
JGL GROUP	1,041	1,103
JGL PHARMA	865	930
JGL d.d.	605	667
Croatia	484	521
Macedonia	5	5
Russia	4	5
Belarus	18	21
Ukraine	52	63
Kazakhstan	41	51
Kosovo	1	1
Affiliated companies	436	436
JGL d.o.o. Beograd – Sopot	20	27
Farmis d.o.o. Sarajevo	26	25
JGL d.o.o. Ljubljana	6	4
Adrialab d.o.o Rijeka	28	28
Ljekarna Pablo Health Institution	148	145
Jadran LLC Moskva	208	207

Overview of the number of employees on 30 June 2020 and 2021 in the JGL Group, JGL Pharma and JGL d.d.

**REPORTING
YEAR**

**MEMBER OF
THE**

**JGL
GROUP**

PHARMACEUTICAL BUSINESS


JADRAN LLC MOSKVA

The operating revenue in the first half of 2021 was HRK 114 million, which is 17% more compared to the same period in 2020. In accordance with market results for the five months of 2021, an increase of 7% was recorded compared to the same period last year, while the relevant market shows a decrease of 2.5%. JGL was the fastest growing foreign pharmaceutical company on the market in May.


The seawater products market, compared to the same period in 2020, shows a decrease of 20%, while the most significant brand of the Company in this market, Aqua Maris, shows a decrease of 4%. It is important to note that, due to the amount of sold boxes of this brand in May and the market share of 35%, Aqua Maris was the leading brand once again. Furthermore, thanks to Aqua Maris Ectoin, an enviable increase of 11% was achieved in a declining market (-8%) compared to 2020. Good results were also achieved with Meralys (+16%) and Optinol (+177%).

Despite the increase in revenue and good market results, the result of the period was negative due to increased costs, and the affiliated company plans to compensate the loss of HRK 10,809,277 in the second half of the year.

17%



Increase in the operating revenue in the Russian market compared to the same period in 2020



FARMIS D.O.O. SARAJEVO

The beginning of 2021 was marked by turbulence caused by the COVID-19 pandemic, a closed market, significantly reduced possibilities to work with customers, as well as an overall decline in the purchasing power of the population. Nevertheless, the operating revenue of the company Farmis at the end of the first half of the year in the market of Bosnia and Herzegovina was HRK 28.7 million, while the profit in the period was HRK 908,177.

JGL D.O.O. BEOGRAD – SOPOT

The first half of the financial year 2021 was marked by further revenue growth of as much as 86% compared to the same period last year. For the first time, the company ended the half-year with a profit of HRK 1,344,899. Total revenue was HRK 9.3 million. In the field of marketing and sales, the company is still focused on pharmacies, consumers, paediatricians, gynaecologists, ENT, and ophthalmologists. A big digital campaign for products Vizol S, Reflustat and Prolife has also been launched.

In the field of production, the company is focused on the production of medicinal products and dietary products, both for the sale on the Serbian market and the surrounding markets. The key to revenue growth in the company's financial year 2021 is the sale of products that were transferred to Sopot during 2020 for all markets: Lactogyn oral capsules, Feminal capsules, Normia capsules and Normia sachets. The result will be additionally strengthened by selling the products to the Hungarian Egis in the second half of the year, whose orders are awaiting the registration certificate.

JADRAN – GALENSKI LABORATORIJ D.O.O. LJUBLJANA

The first half of 2021 in Jadran - Galenski laboratorij d.o.o. Ljubljana was completed with a successful launch of Maresyl HA and record sales in June. Key brands (Aqua Maris, Vizol S) also showed double-digit growth rates in the reporting period. A total revenue of HRK 6.3 million and profit before tax of HRK 451,069 were generated.

PHARMACY AND COSMETICS

LJEKARNA PABLO HEALTH INSTITUTION

The total revenue of the health institution involved in the pharmaceutical business, "Ljekarna Pablo", a chain of 30 pharmacies, reached HRK 92 million in the first half of 2021, which represents a decrease of one percent compared to the same period in 2020. The operating revenue in the period from January to June 2021 amounts to HRK 85 million, which is also a decrease of one percent compared to 2020. The result of the period amounts to HRK 2,309,974.


PABLO D.O.O.

The total revenue of Pablo d.o.o. in the first half of 2021 amounts to HRK 26 thousand, which represents an increase of 47% compared to the same period in 2020. The rental income in the period from January to June 2021 amounts to HRK 2,437.20, which is identical to the rental income in the same period in 2020. The profit of the period amounts to HRK 12,895.


ADRIALAB D.O.O.

The first half of 2021 in Adrialab was marked by significant investments in production capacities. An investment of HRK 2.2 million was realised, which is a necessary prerequisite for the consolidation of the production of cosmetic products at the level of the JGL Group. Applicable regulatory requirements have been fulfilled and new solutions for medicinal products have been obtained, which has enabled the production of syrups of this regulatory category. The marketing focus was on strengthening the leading position of the brand Dječja mast JGL (baby ointment), for which a marketing campaign was designed and modern communication messages of the brand were created.


By mid-2021, the aforementioned was reflected through revenue growth of 4% compared to 2020, which amounts to HRK 10 million, and through profit of HRK 1,739,932. The sales channel of retail chains was marked by revenue growth of 3%, while the pharmacy channel shows a significant decrease compared to the record-breaking 2020 that was marked by the sale of disinfectants. The production for the parent company JGL d.d. was also doubled through consolidation of the production of cosmetic products. Operating profitability (EBITDA) is close to 25%, which demonstrates that costs are actively managed.




SALES RESULTS



The structure of net sales of JGL Pharma by markets in the period from 1 January to 30 June 2021



The structure of net sales of JGL Pharma by brands in the period from 1 January to 30 June 2021




AQUA MARIS®

In the first half of 2021, the net sales of Aqua Maris was HRK 83.5 million, which is a decrease of 33% compared to the previous year.

Nevertheless, this brand still holds the leading position in the JGL Pharma portfolio. The Russian market increased the share in sales of the brand from 53% to 67%, followed by Ukraine with 13%, Belarus with 6%, and Croatia with 6% share.

The structure of the Aqua Maris brand sales by markets in the period from 1 January to 30 June 2021





MERALYS

In the first half of 2021, Meralys achieved net sales in the amount of HRK 21.7 million, which is 8% less compared to the first half of 2020. This is primarily due to decreased sales in Belarus and Kazakhstan. The biggest sales growth occurred in the Russian market, with an increase in sales of 9% compared to the previous year. Russia is also the biggest market for the Meralys brand, with a share in net sales of 49%.

According to the share in sales, the domestic Croatian market is in the second place with 21% share, followed by Belarus with 12% and Ukraine with 9% share.

The structure of the Meralys brand sales by markets in the period from 1 January to 30 June 2021




Акнекутан®

In the first half of 2021, the brand Aknekutan (Isotretinoin) shows an increase in net sales of 33% compared to the first half of 2020. The sales in 2021 amount to HRK 27.8 million, which is HRK 6.9 million more compared to the previous year.

The Russian market still has the biggest share in the sale of Aknekutan, even though the share decreased from 75% to 58% in 2021. The biggest drivers of growth are the markets of Ukraine, with an increase in net sales of HRK 2.7 million, and Kazakhstan, with an increase of HRK 2.3 million compared to the first half of 2020.


The structure of the Aknekutan brand sales by markets in the period from 1 January to 30 June 2021



Vizol S achieved an increase in net sales of 38% in the first six months of 2021. The sales in 2021 amount to HRK 19.1 million, which is an increase of HRK 5.3 million compared to the previous year. The markets showing the biggest growth in sales are Russia, with an increase of HRK 5.7 million, and Croatia, with an increase of HRK 1.1 million compared to the first half of 2020.

The Russian market has the biggest share in the sales of the brand with 29.8% share, followed by the Croatian market with 21.8% share, Ukraine with 19.2%, Belarus with 9.9%, and Kazakhstan with 7.2% share in net sales.

The structure of the Vizol S brand sales by markets in the period from 1 January to 30 June 2021






DRAMINA

After the decrease in sales in the previous year, the net sales of the Dramina brand grew at a rate of 68% and amounted to HRK 12.9 million in the first half of 2021. The biggest growth (71%) occurred in the Russian market that achieved an increase in sales of HRK 3.6 million compared to the previous half-year.

In addition to the biggest growth, the Russian market also demonstrates the biggest share in net sales of the brand of 67%. It is followed by the Croatian market with 7% share, Ukraine with 5% share, and Kazakhstan and Georgia with 4% share.

The structure of the Dramina brand sales by markets in the period from 1 January to 30 June 2021





RISKS, EXPOSURE



AND PROTECTION

In its ordinary course of business, the JGL Group is exposed to various financial risks that are connected with foreign currency, interest rate, credit, market and liquidity risks. The Group is monitoring these risks and trying to reduce their potential effect on the companies' financial exposure. The most significant risks, along with the methods used to manage them, are described below.

FOREIGN CURRENCY RISK

The Group is exposed to risks of foreign exchange rate fluctuations during procurement and sales denominated in foreign currencies. The Group is exposed to a transaction risk, which is the risk of a negative impact of the exchange rate on cash flows from operating activities, as well as a balance sheet risk that manifests as a lower value of net monetary assets in foreign currencies. Currency risk is also present in the presentation of the performance of foreign subsidiaries, which is presented in HRK in the consolidated reports. The dominant share of export in sales results in the exposure to the foreign currency risk in such a manner that foreign currency assets exceed the amount of foreign currency liabilities.

The exposure to foreign currency risk is constantly monitored and hedging instruments are used as necessary. The decision on hedging depends on the currency in which the receivables are denominated, type of the hedging instrument and its price. As at 30/06/2021, the Parent Company did not have any active forward contracts. The Group is mostly exposed to the foreign currency risk arising from the fluctuation of the kuna (HRK) against the euro (EUR) and the rouble (RUB). The risk arising from the fluctuation of the kuna against the Russian rouble is the higher of the two, affecting the parent company JGL d.d. and its affiliate JADRAN LLC at a ratio of 50:50.

Exposure to currency risk of changes in the exchange rate of EUR

JGL d.d. is naturally protected from the effects of changes in the exchange rate of EUR, namely foreign currency assets and liabilities are equal. Also, the movement of the EUR exchange rate against the HRK is less volatile, with an absolute change of less than 1.5% occurring during the year.

JGL d.d. invoices products in Ukraine and Kazakhstan in EUR, but due to the devaluation of the local currency (tenge and hryvnia), there has been a decline in value against the EUR in recent years. This results in a decline in the purchasing power of the local population, which in turn can negatively affect the sale of JGL d.d. products.



Movement of the EUR/HRK exchange rate in the period from 01/01/2021 to 30/06/2021

Source: ECB


Exposure to currency risk of changes in the exchange rate of RUB

JGL d.d. invoices products for the Russian market in the Russian rouble. During the first half of 2021, the exchange rate of the rouble was affected by the prolonged health-economic crisis caused by the COVID-19, the political situation between the USA and Russia, mone-

tary policy of the Central Bank of Russia, and the price per barrel of oil on global markets.

In the first half of 2021, the Russian rouble continues following the volatile trend, but the rise of oil price and increase in interest rates of the Central Bank of Russia have caused the Russian rouble's strengthening towards the end of the half-year.

In 2021, the rouble exchange rate risk will be reduced by holding security stocks in euros, reducing the payment deadline within the Group, reducing the difference between foreign currency assets and liabilities, establishing a policy of managing roubles in the account, and, if necessary, by hedging the EUR-RUB currency pair with forward contracts.



Movement of the EUR/HRK exchange rate in the period from 01/01/2021 to 30/06/2021

Source: ECB

LIQUIDITY RISK

The liquidity risk is manifested as the risk that the JGL Group will not be able to fulfil its obligations towards creditors or that it will not be able to collect cash fast enough and sell its less liquid assets (receivables and inventories). The Group manages liquidity risk by planning cash flow on a monthly basis

and by maintaining a sufficient amount of liquid assets and working capital. This risk is further mitigated by contracting favourable credit lines with various commercial banks, allowing for a fast withdrawal of short-term funds under more favourable conditions.

In 2020, credit lines in EUR were approved and contracted with commercial banks in the total amount of EUR 9,500,000. These lines are used as a liquidity reserve and there was no need for their use in the same year.

INTEREST RATE RISK

As the JGL Group does not have significant assets that generate interest income, income and cash flow from operating activities are not significantly dependent on changes in market interest rates. The Group's interest rate risk arises from long-term loans and bonds issued.

Within the JGL Group, the Parent Company is indebted and therefore bears most of the interest rate risk. If we take into account that most of the long-term interest debt is contracted at a fixed interest rate, the Parent Company is minimally exposed to the interest rate change risk.

This, in turn, potentially exposes JGL to the fair value interest rate risk. JGL does not use derivative instruments to actively hedge its exposure to interest rate risk (cash flow interest rate risk and fair value interest rate risk), but it actively monitors market interest rate movements and takes the necessary measures to reduce interest rates if they are too high through refinancing mechanisms with another lender or a reduction in the interest rate with an existing lender.

For the purposes of short-term financing, JGL uses funds from the lines of short-term credit arranged with its commercial banks at favourable interest rates which are reviewed annually.

RISK OF DEBT

The JGL Group manages its capital by regulating the proportion of self-financing versus financing from external sources. Financing from external sources is based on non-current assets with favourable interest rates, and does not represent a burden on the liquidity. With regard to debt type, the Parent Company has long-term liabilities for received loans, leasing and issued bonds.

Long-term loan liabilities consist of two long-term loans obtained from the Croatian Bank for Reconstruction and Development. The liability for the long-term HBOR loan used to finance an investment in a new production facility Svilno 2 amounts to HRK 166,179,216. Repayment of the principal began in 2019, and in 2020 an addendum to the contract was signed, reducing the interest rate and driving down financing costs.

In 2020, the Parent Company launched a new investment, INTEGRA 2020, which includes the expansion of production capacities, equipment of the development laboratory, construction of a new pilot facility, refurbishment of the office space and the construction of a logistics centre. The investment is partially self-financed and partially financed by a long-term loan of the Croatian Bank for Reconstruction and Development in the amount of HRK 279,830,372.74 with a favourable interest rate. The estimated duration of the investment and drawing period of the loan is until 30 June 2022. By 30 June 2021, HRK 64,913,732 was utilised.

On 30 June 2021, the parent company JGL has liabilities under the issue of bonds under the code HRJDG-LO24XA2, in the amount of HRK 130,000,000 with a maturity date of 18 December 2024; the interest on these bonds is fixed and amounts to 1.75%.

Long-term lease liabilities are divided into those for operating and financial leasing. The contracts are for

four or five years with favourable fixed interest rates. The decrease of debt and shorter deadlines for collection of receivables resulted in financial stability, company liquidity, creditworthiness, and a good net debt-to-capital ratio.

ACCOUNTS RECEIVABLE RISK

The accounts receivable risk is significantly diversified through the distribution of the JGL Group receivables by various geographical areas and customers (CIS, SEE, global markets). The Group tries to protect itself from this risk by obtaining payment insurance instruments and by selecting customers based on the evaluation of their creditworthiness, as well as by insuring export receivables.

Receivables from Russia are being insured since 2003, and trade receivables from other countries (CIS, SEE, global markets) since 2011. The receivables of the affiliate company Jadran LLC are insured in Russia through the insurance company Euler Hermes. The total insured credit limit for all customers in Russia in 2021 is around EUR 26.5 million.

Receivables of JGL d.d. are insured with the Croatian Bank for Reconstruction and Development (HBOR) and the Croatian Credit Insurance (HKO). Most foreign trade receivables that have an arranged deferral of payment are insured, with the exception of several customers in the CIS region and the EU. Information on customers is collected together with insurers, and the risk, creditworthiness and liquidity of insured customers are systematically monitored. All insured customers have agreed credit limits that are constantly monitored, which is how the JGL Group's exposure to each customer, as well as the collection of receivables, is controlled.

The limits have been approved by the insurers of the JGL Group, and are continuously revised and changed as required.

In the last few years, the Group has recorded a constant increase in insured amounts, which is a consequence of the growth in turnover and the increase in insured amounts with existing customers and the introduction of new customers in insurance. Despite the coronavirus crisis, there were no claims related to the insurance of accounts receivable in 2020 and 2021.

An overview of insured amounts by country as at 30 June 2021, in EUR


Country	EUR
Kazakhstan	5,700,000
Ukraine	5,000,000
Belarus	2,770,000
Other Countries	4,070,000
Total	17,540,000

The Parent Company is part of the healthcare system of the Republic of Croatia and is indirectly subject to the risk of collection maturity related to collection from customers within the Croatian Health Insurance

Fund (CHIF) system. JGL manages this risk through the market position of the affiliate HI Ljekarna Pablo, which bases its purchase from wholesalers on the share of each wholesaler in the sales of the parent company JGL d.d. JGL ensures nearly 90% of its pharmaceutical wholesale in Croatia by directing the purchase policy of its affiliate company, so the payment security risk is reduced to a minimum.

Although the JGL Group does not deal directly with the healthcare system, due to operating with wholesalers, the stated payment collection deadlines in healthcare significantly affect the Group's operations. In the last few years, the system of financing expenditure in Croatian healthcare has been recording a constant decrease in payment deadlines, from the former 150 to 74 days in 2019, only to rise again to 120 days in 2020 and 2021 due to the coronavirus crisis.

In Russia, the most important export market, the average collection from wholesalers is also 120 days. The situation is similar in other markets. In the home countries of other member companies, the average customer collection period ranges from 30 to 90 days, whereas the average collection period from wholesalers has been extended and typically ranges from 90 to 120 days.





FUTURE COMPANY DEVELOPMENT

Despite difficult and reduced access to healthcare in all countries in which we operate and the decline in the purchasing power of the population due to COVID-19 pandemic, the JGL Group achieved stable financial results in the first half of 2021. The coronavirus crisis had a profound impact on the economy, entrepreneurs and companies, and degraded operating conditions yet again confirmed the significance of the industry based on high technology.

Even though it was expected that 2021 will be turbulent in terms of business, JGL boldly entered a new operative phase that includes new investments, advance into digitalisation, refining priorities for new pipeline products, defining solid but flexible go-to-market strategies for key therapeutic areas and brands based on patient and consumer needs and supported by medical and scientific data.

Even though we also had to deal with the consequences of the coronavirus crisis, especially in terms of a drastic decline in the cold and flu season, as well as challenges with payment in the healthcare system, they have not prevented us from achieving our priority goals. We demonstrated a high level of flexibility and adaptability and proved that many years of investment in a team of experts bring results on which we base optimism for the future.

We expect that new opportunities will open up in the second half of the year and we believe in the proper direction of our potentials, while continuing to be fast, efficient and competitive. Our stable position on the market gives us security and stability for the future. We will continue to invest in the Integra 2020 project, with which we firmly secure the future development and technological capacities of the company.

We continue our chosen direction by following innovative practices, strengthening the growth in competitiveness and export production potentials of our company, but also of the Croatian pharmaceutical industry, as well as the Republic of Croatia itself.

Mislav Vučić
Executive Director

FINANCIAL STATEMENTS

JGL GROUP

BALANCE SHEET	40
STATEMENT OF PROFIT OR LOSS	44
STATEMENT OF CASH FLOWS – DIRECT METHOD	48
STATEMENT OF CHANGES IN EQUITY	50
NOTES ACCOMPANYING THE FINANCIAL STATEMENTS – PFI	52

BALANCE SHEET
balance as at 30.6.2021
in HRK

Submitter:
JGL GROUP

Item 1	ADP code 2	Last day of the preceding business year 3	At the reporting date of the current period 4
ASSETS			
A	RECEIVABLES FOR SUBSCRIBED CAPITAL UNPAID	001	
B	FIXED ASSETS (ADP 003+010+020+031+036)	002	697,893,535
I.	INTANGIBLE ASSETS (ADP 004 to 009)	003	123,755,933
	Research and development	004	13,614,834
	Concessions, patents, licences, trademarks, software and other rights	005	44,836,626
	Goodwill	006	21,824,660
	Advances for the purchase of intangible assets	007	0
	Intangible assets in preparation	008	35,581,985
	Other intangible assets	009	7,897,828
II.	TANGIBLE ASSETS (ADP 011 to 019)	010	551,609,677
	Land	011	46,051,425
	Buildings	012	255,483,499
	Plant and equipment	013	190,148,813
	Tools, working inventory and transportation assets	014	18,557,163
	Biological assets	015	0
	Advances for the purchase of tangible assets	016	0
	Tangible assets in preparation	017	22,700,204
	Other tangible assets	018	1,116,036
	Investment property	019	17,552,537
III.	FIXED FINANCIAL ASSETS (ADP 021 to 030)	020	1,788,954
	Investments in holdings (shares) of undertakings within the group	021	0
	Investments in other securities of undertakings within the group	022	0
	Loans, deposits, etc. to undertakings within the group	023	0
	Investments in holdings (shares) of companies linked by virtue of participating interests	024	606,379
	Investment in other securities of companies linked by virtue of participating interests	025	0
	Loans, deposits etc. to companies linked by virtue of participating interests	026	0
	Investments in securities	027	1,182,575
	Loans, deposits, etc. given	028	0
	Other investments accounted for using the equity method	029	0
	Other fixed financial assets	030	0
IV.	RECEIVABLES (ADP 032 to 035)	031	406
	Receivables from undertakings within the group	032	0
	Receivables from companies linked by virtue of participating interests	033	0

BALANCE SHEET
balance as at 30.6.2021
in HRK

Submitter:
JGL GROUP

Item 1	ADP code 2	Last day of the preceding business year 3	At the reporting date of the current period 4
Customer receivables	034	0	0
Other receivables	035	406	403
V. DEFERRED TAX ASSETS	036	20,738,565	25,409,557
C CURRENT ASSETS (ADP 038+046+053+063)	037	623,501,124	575,459,347
I. INVENTORIES (ADP 039 to 045)	038	216,053,529	271,325,313
Raw materials and consumables	039	68,743,033	91,554,125
Production in progress	040	83,425	436,667
Finished goods	041	73,426,340	99,829,784
Merchandise	042	73,736,347	79,504,737
Advances for inventories	043	64,384	0
Fixed assets held for sale	044	0	0
Biological assets	045	0	0
II. RECEIVABLES (ADP 047 to 052)	046	355,049,665	276,356,885
Receivables from undertakings within the group	047	0	0
Receivables from companies linked by virtue of participating interests	048	0	0
Customer receivables	049	311,705,245	217,806,529
Receivables from employees and members of the undertaking	050	22,978	96,594
Receivables from government and other institutions	051	17,877,180	24,613,925
Other receivables	052	25,444,262	33,839,837
III. CURRENT FINANCIAL ASSETS (ADP 054 to 062)	053	19,806,672	289,385
Investments in holdings (shares) of undertakings within the group	054	0	0
Investments in other securities of undertakings within the group	055	0	0
Loans, deposits, etc. to undertakings within the group	056	0	0
Investments in holdings (shares) of companies linked by virtue of participating interests	057	0	0
Investment in other securities of companies linked by virtue of participating interests	058	0	0
Loans, deposits etc. to companies linked by virtue of participating interests	059	0	0
Investments in securities	060	0	0
Loans, deposits, etc. given	061	97,686	289,385
Other financial assets	062	19,708,986	0
IV. CASH AT BANK AND IN HAND	063	32,591,258	27,487,764
D PREPAID EXPENSES AND ACCRUED INCOME	064	5,586,413	4,407,182
E TOTAL ASSETS (ADP 001+002+037+064)	065	1,326,981,072	1,342,686,515
F OFF-BALANCE SHEET ITEMS	066	66,669,661	114,435,590

BALANCE SHEET
balance as at 30.6.2021
in HRK

Submitter:
JGL GROUP

Item	ADP code	Last day of the preceding business year	At the reporting date of the current period
1	2	3	4
LIABILITIES			
A CAPITAL AND RESERVES	067	681,885,086	677,914,625
(AOP 068 do 070+076+077+083+086+089)			
I. INITIAL (SUBSCRIBED) CAPITAL	068	120,560,000	120,560,000
II. CAPITAL RESERVES	069	21,836,295	21,836,295
III. RESERVES FROM PROFIT (AOP 071+072-073+074+075)	070	51,297,160	54,945,344
1 Legal reserves	071	48,113,133	51,761,317
2 Reserves for treasury shares	072	8,738,948	8,419,148
3 Treasury shares and holdings (deductible item)	073	-7,695,700	-7,375,900
4 Statutory reserves	074	0	0
5 Other reserves	075	2,140,779	2,140,779
IV. REVALUATION RESERVES	076	0	0
V. FAIR VALUE RESERVES AND OTHER (AOP 078 do 082)	077	699,976	72,880
1 Financial assets at fair value through other comprehensive income (i.e. available for sale)	078	0	0
2 Cash flow hedge - effective portion	079	0	0
3 Hedge of a net investment in a foreign operation - effective portion	080	0	0
4 Other fair value reserves	081	0	0
5 Exchange differences arising from the translation of foreign operations (consolidation)	082	699,976	72,880
VI. RETAINED PROFIT OR LOSS BROUGHT FORWARD (ADP 084-085)	083	421,829,846	473,074,254
1 Retained profit	084	421,829,846	473,074,254
2 Loss brought forward	085	0	0
VII. PROFIT OR LOSS FOR THE BUSINESS YEAR (ADP 087-088)	086	65,661,809	7,425,852
1 Profit for the business year	087	65,661,809	7,425,852
2 Loss for the business year	088	0	0
VIII. MINORITY (NON-CONTROLLING) INTEREST	089	0	0
B PROVISIONS (ADP 091 to 096)	090	3,428,857	3,428,857
1 Provisions for pensions, termination benefits and similar obligations	091	2,603,636	2,603,636
2 Provisions for tax liabilities	092	0	0
3 Provisions for ongoing legal cases	093	825,221	825,221
4 Provisions for renewal of natural resources	094	0	0
5 Provisions for warranty obligations	095	0	0
6 Other provisions	096	0	0

BALANCE SHEET
balance as at 30.6.2021
in HRK

Submitter:
JGL GROUP

Item 1	ADP code 2	Last day of the preceding business year 3	At the reporting date of the current period 4
C LONG-TERM LIABILITIES (ADP 098 to 108)	097	345,481,146	392,119,812
1 Liabilities to undertakings within the group	098	0	0
2 Liabilities for loans, deposits, etc. of undertakings within the group	099	0	0
3 Liabilities to companies linked by virtue of participating interests	100	0	0
4 Liabilities for loans, deposits etc. of companies linked by virtue of participating interests	101	0	0
5 Liabilities for loans, deposits etc.	102	0	0
6 Liabilities to banks and other financial institutions	103	213,564,675	259,963,506
7 Liabilities for advance payments	104	0	0
8 Liabilities to suppliers	105	0	0
9 Liabilities for securities	106	128,284,569	128,500,970
10 Other long-term liabilities	107	0	0
11 Deferred tax liability	108	3,631,902	3,655,336
D SHORT-TERM LIABILITIES (ADP 110 to 123)	109	274,991,000	237,216,833
1 Liabilities to undertakings within the group	110	0	0
2 Liabilities for loans, deposits, etc. of undertakings within the group	111	0	0
3 Liabilities to companies linked by virtue of participating interests	112	0	0
4 Liabilities for loans, deposits etc. of companies linked by virtue of participating interests	113	0	0
5 Liabilities for loans, deposits etc.	114	0	0
6 Liabilities to banks and other financial institutions	115	59,699,828	37,736,771
7 Liabilities for advance payments	116	2,492,863	5,457,936
8 Liabilities to suppliers	117	173,925,384	163,023,043
9 Liabilities for securities	118	4,000,000	6,000,000
10 Liabilities to employees	119	17,212,386	8,342,278
11 Taxes, contributions and similar liabilities	120	16,311,269	13,937,584
12 Liabilities arising from the share in the result	121	20,100	193,900
13 Liabilities arising from fixed assets held for sale	122	0	0
14 Other short-term liabilities	123	1,329,170	2,525,321
E ACCRUALS AND DEFERRED INCOME	124	21,194,983	32,006,388
F TOTAL – LIABILITIES (ADP 067+090+097+109+124)	125	1,326,981,072	1,342,686,515
G OFF-BALANCE SHEET ITEMS	126	66,669,661	114,435,590

STATEMENT OF PROFIT OR LOSS
for the period 1.1.2021 to 30.6.2021
in HRK

Submitter:
JGL GROUP

Item	ADP code	Same period of the previous year	Current period
1	2	3	4
I. OPERATING INCOME (ADP 002 to 006)	001	453,296,100	411,974,598
1 Income from sales with undertakings within the group	002	0	0
2 Income from sales (outside group)	003	441,861,302	402,292,952
3 Income from the use of own products, goods and services	004	0	0
4 Other operating income with undertakings within the group	005	0	0
5 Other operating income (outside the group)	006	11,434,798	9,681,646
II. OPERATING EXPENSES (ADP 08+009+013+017+018+019+022+029)	007	406,168,419	403,449,151
1 Changes in inventories of work in progress and finished goods	008	-17,995,692	-30,357,448
2 Material costs (ADP 010 to 012)	009	287,553,786	296,576,764
a) Costs of raw materials and consumables	010	97,916,038	95,405,246
b) Costs of goods sold	011	107,260,626	112,462,773
c) Other external costs	012	82,377,122	88,708,745
3 Staff costs (ADP 014 to 016)	013	85,123,795	86,864,826
a) Net salaries and wages	014	54,797,465	54,648,171
b) Tax and contributions from salary costs	015	18,219,384	19,070,815
c) Contributions on salaries	016	12,106,946	13,145,840
4 Depreciation	017	24,002,183	24,662,710
5 Other costs	018	15,060,858	19,005,220
6 Value adjustments (ADP 020+021)	019	0	0
a) fixed assets other than financial assets	020	0	0
b) current assets other than financial assets	021	0	0
7 Provisions (ADP 023 to 028)	022	0	0
a) Provisions for pensions, termination benefits and similar obligations	023	0	0
b) Provisions for tax liabilities	024	0	0
c) Provisions for ongoing legal cases	025	0	0
d) Provisions for renewal of natural resources	026	0	0
e) Provisions for warranty obligations	027	0	0
f) Other provisions	028	0	0
8 Other operating expenses	029	12,423,489	6,697,079
III. FINANCIAL INCOME (ADP 031 to 040)	030	7,366,876	5,147,620
1 Income from investments in holdings (shares) of undertakings within the group	031	0	0
2 Income from investments in holdings (shares) of companies linked by virtue of participating interests	032	0	0

STATEMENT OF PROFIT OR LOSS
for the period 1.1.2021 to 30.6.2021
in HRK

Submitter:
JGL GROUP

Item	ADP code	Same period of the previous year	Current period
1	2	3	4
3 Income from other long-term financial investment and loans granted to undertakings within the group	033	0	0
4 Other interest income from operations with undertakings within the group	034	0	0
5 Exchange rate differences and other financial income from operations with undertakings within the group	035	0	0
6 Income from other long-term financial investments and loans	036	0	0
7 Other interest income	037	268,834	126,216
8 Exchange rate differences and other financial income	038	7,046,796	4,995,582
9 Unrealised gains (income) from financial assets	039	0	0
10 Other financial income	040	51,246	25,822
IV. FINANCIAL EXPENSES (ADP 042 to 048)	041	26,508,071	6,247,215
1 Interest expenses and similar expenses with undertakings within the group	042	0	0
2 Exchange rate differences and other expenses from operations with undertakings within the group	043	0	0
3 Interest expenses and similar expenses	044	7,067,984	4,936,737
4 Exchange rate differences and other expenses	045	17,682,325	1,310,478
5 Unrealised losses (expenses) from financial assets	046	1,757,762	0
6 Value adjustments of financial assets (net)	047	0	0
7 Other financial expenses	048	0	0
V. SHARE IN PROFIT FROM UNDERTAKINGS LINKED BY VIRTUE OF PARTICIPATING INTERESTS	049	0	0
VI. SHARE IN PROFIT FROM JOINT VENTURES	050	0	0
VII. SHARE IN LOSS OF COMPANIES LINKED BY VIRTUE OF PARTICIPATING INTEREST	051	0	0
VIII. SHARE IN LOSS OF JOINT VENTURES	052	0	0
IX. TOTAL INCOME (ADP 001+030+049 +050)	053	460,662,976	417,122,218
X. TOTAL EXPENDITURE (ADP 007+041+051 + 052)	054	432,676,490	409,696,366
XI. PRE-TAX PROFIT OR LOSS (ADP 053-054)	055	27,986,486	7,425,852
1 Pre-tax profit (ADP 053-054)	056	27,986,486	7,425,852
2 Pre-tax loss (ADP 054-053)	057	0	0
XII. INCOME TAX	058	-1,778,056	0
XIII. PROFIT OR LOSS FOR THE PERIOD (ADP 055-059)	059	29,764,542	7,425,852
1 Profit for the period (ADP 055-059)	060	29,764,542	7,425,852
2 Loss for the period (ADP 059-055)	061	0	0

STATEMENT OF PROFIT OR LOSS
for the period 1.1.2021 to 30.6.2021
in HRK

Submitter:
JGL GROUP

Item	ADP code	Same period of the previous year	Current period
1	2	3	4
DISCONTINUED OPERATIONS (to be filled in by undertakings subject to IFRS only with discontinued operations)			
XIV. PRE-TAX PROFIT OR LOSS OF DISCONTINUED OPERATIONS (ADP 063-064)	062		0
1 Pre-tax profit from discontinued operations	063		0
2 Pre-tax loss on discontinued operations	064		0
XV. INCOME TAX OF DISCONTINUED OPERATIONS	065		0
1 Discontinued operations profit for the period (ADP 062-065)	066		0
2 Discontinued operations loss for the period (ADP 065-062)	067		0
TOTAL OPERATIONS (to be filled in only by undertakings subject to IFRS with discontinued operations)			
XVI. PRE-TAX PROFIT OR LOSS (ADP 055-+062)	068		0
1 Pre-tax profit (ADP 068)	069		0
2 Pre-tax loss (ADP 068)	070		0
XVII. INCOME TAX (ADP 058+065)	071		0
XVIII. PROFIT OR LOSS FOR THE PERIOD (ADP 068-071)	072		0
1 Profit for the period (ADP 068-071)	073		0
2 Loss for the period (ADP 071-068)	074		0
APPENDIX to the P&L (to be filled in by undertakings that draw up consolidated annual financial statements)			
XIX. PROFIT OR LOSS FOR THE PERIOD (ADP 076+077)	075	29,764,542	7,425,852
1 Attributable to owners of the parent	076	29,764,542	7,425,852
2 Attributable to minority (non-controlling) interest	077	0	0
STATEMENT OF OTHER COMPREHENSIVE INCOME (to be filled in by undertakings subject to IFRS)			
I. PROFIT OR LOSS FOR THE PERIOD	078	29,764,542	7,425,852
II. OTHER COMPREHENSIVE INCOME/LOSS BEFORE TAX (ADP 80+ 87)	079	294,201	-627,096
III. Items that will not be reclassified to profit or loss (ADP 081 to 085)	080	0	0
1 Changes in revaluation reserves of fixed tangible and intangible assets	081	0	0
2 Gains or losses from subsequent measurement of equity instruments at fair value through other comprehensive income	082	0	0

STATEMENT OF PROFIT OR LOSS
for the period 1.1.2021 to 30.6.2021
in HRK

Submitter:
JGL GROUP

Item	ADP code	Same period of the previous year	Current period
1	2	3	4
3 Fair value changes of financial liabilities at fair value through statement of profit or loss, attributable to changes in their credit risk	083	0	0
4 Actuarial gains/losses on the defined benefit obligation	084	0	0
5 Other items that will not be reclassified	085	0	0
6 Income tax relating to items that will not be reclassified	086	0	0
IV. Items that may be reclassified to profit or loss (ADP 088 to 095)	087	294,201	-627,096
1 Exchange rate differences from translation of foreign operations	088	294,201	-627,096
2 Gains or losses from subsequent measurement of debt securities at fair value through other comprehensive income	089	0	0
3 Profit or loss arising from effective cash flow hedging	090	0	0
4 Profit or loss arising from effective hedge of a net investment in a foreign operation	091	0	0
5 Share in other comprehensive income/loss of companies linked by virtue of participating interests	092	0	0
6 Changes in fair value of the time value of option	093	0	0
7 Changes in fair value of forward elements of forward contracts	094	0	0
8 Other items that may be reclassified to profit or loss	095	0	0
9 Income tax relating to items that may be reclassified to profit or loss	096	0	0
V. NET OTHER COMPREHENSIVE INCOME OR LOSS (ADP 080+087- 086 - 096)	097	294,201	-627,096
VI. COMPREHENSIVE INCOME OR LOSS FOR THE PERIOD (ADP 078+097)	098	30,058,743	6,798,756
APPENDIX to the Statement on comprehensive income (to be filled in by undertakings that draw up consolidated statements)			
VI. COMPREHENSIVE INCOME OR LOSS FOR THE PERIOD (ADP 100+101)	099	30.058.743	6,798,756
1 Attributable to owners of the parent	100	30.058.743	6,798,756
2 Attributable to minority (non-controlling) interest	101		0

STATEMENT OF CASH FLOWS - DIRECT METHOD
for the period 1.1.2021 to 30.6.2021
in HRK

Submitter:
JGL GROUP

Item	ADP code	Same period of the previous year	Current period
1	2	3	4
Cash flow from operating activities			
1 Cash receipts from customers	001	535,231,889	520,518,512
2 Cash receipts from royalties, fees, commissions and other revenue	002	0	0
3 Cash receipts from insurance premiums	003	283,596	297,170
4 Cash receipts from tax refund	004	7,242,834	8,210,526
5 Other cash receipts from operating activities	005	1,471,417	1,110,780
I. Total cash receipts from operating activities (ADP 001 to 005)	006	544,229,736	530,136,988
1 Cash payments to suppliers	007	-338,589,114	-368,216,856
2 Cash payments to employees	008	-68,428,047	-75,013,178
3 Cash payments for insurance premiums	009	-884,323	-1,309,513
4 Interest paid	010	-6,339,177	-3,536,408
5 Income tax paid	011	-603,425	-1,142,757
6 Other cash payments from operating activities	012	-62,781,265	-60,185,804
II. Total cash payments from operating activities (ADP 007 to 012)	013	-477,625,351	-509,404,516
A NET CASH FLOW FROM OPERATING ACTIVITIES (ADP 006 + 013)	014	66,604,385	20,732,472
Cash flow from investment activities			
1 Cash receipts from sales of fixed tangible and intangible assets	015	255,336	641,724
2 Cash receipts from sales of financial instruments	016	0	19,411,346
3 Interest received	017	755	124,995
4 Dividends received	018	0	0
5 Cash receipts from the repayment of loans and deposits	019	80,600	2,100
6 Other cash receipts from investment activities	020	214,272,197	0
III. Total cash receipts from investment activities (ADP 015 to 020)	021	214,608,888	20,180,165
1 Cash payments for the purchase of fixed tangible and intangible assets	022	-13,514,219	-49,283,072
2 Cash payments for the acquisition of financial instruments	023	-44,575,176	0
3 Cash payments for loans and deposits	024	-80,000	-78,844
4 Acquisition of a subsidiary, net of cash acquired	025	0	0
5 Other cash payments from investment activities	026	-223,667,700	0
IV. Total cash payments from investment activities (ADP 022 to 026)	027	-281,837,095	-49,361,916
B NET CASH FLOW FROM INVESTMENT ACTIVITIES (ADP 021 + 027)	028	-67,228,207	-29,181,751
Cash flow from financing activities			
1 Cash receipts from the increase in initial (subscribed) capital	029	0	0
2 Cash receipts the from issue of equity financial instruments and debt financial instruments	030	0	0
3 Cash receipts from credit principals, loans and other borrowings	031	0	40,485,485
4 Other cash receipts from financing activities	032	70,000	0

STATEMENT OF CASH FLOWS - DIRECT METHOD
for the period 1.1.2021 to 30.6.2021
in HRK

Submitter:
JGL GROUP

Item	ADP code	Same period of the previous year	Current period
1	2	3	4
V. Total cash receipts from financing activities (ADP 029 to 032)	033	70,000	40,485,485
1 Cash payments for the repayment of credit principals, loans and other borrowings and debt financial instruments	034	-13,334,393	-13,294,337
2 Cash payments for dividends	035	-10,052,937	-12,277,551
3 Cash payments for finance lease	036	-14,218,826	-11,775,588
4 Cash payments for the redemption of own shares and decrease in initial (subscribed) capital	037	-206,700	-60,400
5 Other cash payments from financing activities	038	-100,000	0
VI. Total cash payments from financing activities (ADP 034 to 038)	039	-37,912,856	-37,407,876
C NET CASH FLOW FROM FINANCING ACTIVITIES (ADP 033 +039)	040	-37,842,856	3,077,609
1 Unrealised exchange rate differences in respect of cash and cash equivalents	041	1,327,715	268,176
D NET INCREASE OR DECREASE IN CASH FLOWS (ADP 014 + 028 + 040 + 041)	042	-37,138,963	-5,103,494
E CASH AND CASH EQUIVALENTS AT THE BEGINNING OF THE PERIOD	043	85,193,456	32,591,258
F CASH AND CASH EQUIVALENTS AT THE END OF THE PERIOD (ADP 042+043)	044	48,054,493	27,487,764

STATEMENT OF CHANGES IN EQUITY
for the period 1.1.2021 to 30.6.2021
in HRK

Submitter:
JGL GROUP

Item	ADP code	ATTRIBUTABLE TO OWNERS OF THE PARENT																	Minority (non-controlling) interest	Total capital and reserves
		Initial (subscribed) capital	Capital reserves	Legal reserves	Reserves for treasury shares	Treasury shares and holdings (deductible item)	Statutory reserves	Other reserves	Revaluation reserves	Fair value of financial assets through other comprehensive income (available for sale)	Cash flow hedge - effective portion	Hedge of a net investment in a foreign operation - effective portion	Other fair value reserves	Exchange rate differences from translation of foreign operations	Retained profit / loss brought forward	Profit/loss for the business year	Total attributable to owners of the parent			
1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18 (3 do 6 - 7 + 8 do 17)	19	20 (18+19)	
PREVIOUS PERIOD																				
1		01	119,255,000	16,720,695	42,107,648	8,316,947	7,273,700	0	2,140,779	0	0	0	0	681,944	364,571,465	78,442,340	624,963,118	0	624,963,118	
2	Changes in accounting policies	02	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
3	Correction of errors	03	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
4	Balance on the first day of the previous business year (restated) (ADP 01 to 03)	04	119,255,000	16,720,695	42,107,648	8,316,947	7,273,700	0	2,140,779	0	0	0	0	681,944	364,571,465	78,442,340	624,963,118	0	624,963,118	
5	Profit/loss of the period	05	0	0	0	0	0	0	0	0	0	0	0	0	0	29,764,542	29,764,542	0	29,764,542	
6	Exchange rate differences from translation of foreign operations	06	0	0	0	0	0	0	0	0	0	0	0	294,201	0	0	294,201	0	294,201	
7	Changes in revaluation reserves of fixed tangible and intangible assets	07	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
8	Gains or losses from subsequent measurement of financial assets at fair value through other comprehensive income (available for sale)	08	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
9	Profit or loss arising from effective cash flow hedge	09	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
10	Profit or loss arising from effective hedge of a net investment in a foreign operation	10	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
11	Share in other comprehensive income/loss of companies linked by virtue of participating interests	11	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
12	Actuarial gains/losses on the defined benefit obligation	12	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
13	Other changes in equity unrelated to owners	13	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
14	Tax on transactions recognised directly in equity	14	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
15	Decrease in initial (subscribed) capital (other than arising from the pre-bankruptcy settlement procedure or from the reinvestment of profit)	15	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
16	Decrease in initial (subscribed) capital arising from the pre-bankruptcy settlement procedure	16	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
17	Decrease in initial (subscribed) capital arising from the reinvestment of profit	17	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
18	Redemption of treasury shares/holdings	18	0	0	0	-163,000	-163,000	0	0	0	0	0	0	0	792,060	0	792,060	0	792,060	
19	Payments from members/shareholders	19	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
20	Payment of share in profit/dividend	20	0	0	0	0	0	0	0	0	0	0	0	0	-10,094,337	0	-10,094,337	0	-10,094,337	
21	Other distributions and payments to members/shareholders	21	0	0	0	0	0	0	0	0	0	0	0	0	-1,115,136	0	-1,115,136	0	-1,115,136	
22	Transfer to reserves according to the annual schedule	22	0	0	6,005,485	0	0	0	0	0	0	0	0	0	72,436,854	-78,442,340	-1	0	-1	
23	Increase in reserves arising from the pre-bankruptcy settlement procedure	23	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
24	Balance on the last day of the previous business year reporting period (ADP 04 to 23)	24	119,255,000	16,720,695	48,113,133	8,153,947	7,110,700	0	2,140,779	0	0	0	0	976,145	426,590,906	29,764,542	644,604,447	0	644,604,447	
APPENDIX TO THE STATEMENT OF CHANGES IN EQUITY (to be filled in by undertakings that draw up financial statements in accordance with the IFRS)																				
I.	OTHER COMPREHENSIVE INCOME OF THE PREVIOUS PERIOD, NET OF TAX (ADP 06 to 14)	25	0	0	0	0	0	0	0	0	0	0	0	294,201	0	0	294,201	0	294,201	
II.	COMPREHENSIVE INCOME OR LOSS FOR THE PREVIOUS PERIOD (ADP 05+25)	26	0	0	0	0	0	0	0	0	0	0	0	294,201	0	29,764,542	30,058,743	0	30,058,743	
III.	TRANSACTIONS WITH OWNERS IN THE PREVIOUS PERIOD RECOGNISED DIRECTLY IN EQUITY (ADP 15 to 23)	27	0	0	6,005,485	-163,000	-163,000	0	0	0	0	0	0	0	62,019,441	-78,442,340	-10,417,414	0	-10,417,414	

STATEMENT OF CHANGES IN EQUITY
for the period 1.1.2021 to 30.6.2021
in HRK

Submitter:
JGL GROUP

Item	ADP code	ATTRIBUTABLE TO OWNERS OF THE PARENT																	Minority (non-controlling) interest	Total capital and reserves
		Initial (subscribed) capital	Capital reserves	Legal reserves	Reserves for treasury shares	Treasury shares and holdings (deductible item)	Statutory reserves	Other reserves	Revaluation reserves	Fair value of financial assets through other comprehensive income (available for sale)	Cash flow hedge - effective portion	Hedge of a net investment in a foreign operation - effective portion	Other fair value reserves	Exchange rate differences from translation of foreign operations	Retained profit / loss brought forward	Profit/loss for the business year	Total attributable to owners of the parent			
1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18 (3 do 6 - 7 + 8 do 17)	19	20 (18+19)	
CURRENT PERIOD																				
1		28	120,560,000	21,836,295	48,113,133	8,738,948	7,695,700	0	2,140,779	0	0	0	0	699,976	421,829,846	65,661,809	681,885,086	0	681,885,086	
2	Changes in accounting policies	29	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
3	Correction of errors	30	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
4	Balance on the first day of the current business year (restated) (AOP 28 to 30)	31	120,560,000	21,836,295	48,113,133	8,738,948	7,695,700	0	2,140,779	0	0	0	0	699,976	421,829,846	65,661,809	681,885,086	0	681,885,086	
5	Profit/loss of the period	32	0	0	0	0	0	0	0	0	0	0	0	0	0	7,425,852	7,425,852	0	7,425,852	
6	Exchange rate differences from translation of foreign operations	33	0	0	0	0	0	0	0	0	0	0	0	-627,096	0	0	-627,096	0	-627,096	
7	Changes in revaluation reserves of fixed tangible and intangible assets	34	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
8	Gains or losses from subsequent measurement of financial assets at fair value through other comprehensive income (available for sale)	35	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
9	Profit or loss arising from effective cash flow hedge	36	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
10	Profit or loss arising from effective hedge of a net investment in a foreign operation	37	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
11	Share in other comprehensive income/loss of companies linked by virtue of participating interests	38	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
12	Actuarial gains/losses on the defined benefit obligation	39	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
13	Other changes in equity unrelated to owners	40	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
14	Tax on transactions recognised directly in equity	41	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
15	Decrease in initial (subscribed) capital (other than arising from the pre-bankruptcy settlement procedure or from the reinvestment of profit)	42	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
16	Decrease in initial (subscribed) capital arising from the pre-bankruptcy settlement procedure	43	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
17	Decrease in initial (subscribed) capital arising from the reinvestment of profit	44	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
18	Redemption of treasury shares/holdings	45	0	0	0	-319,800	-319,800	0	0	0	0	0	0	0	1,779,884	0	1,779,884	0	1,779,884	
19	Payments from members/shareholders	46	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
20	Payment of share in profit/dividend	47	0	0	0	0	0	0	0	0	0	0	0	0	-12,451,351	0	-12,451,351	0	-12,451,351	
21	Other distributions and payments to members/shareholders	48	0	0	0	0	0	0	0	0	0	0	0	0	-97,750	0	-97,750	0	-97,750	
22	Carryforward per annual plan	49	0	0	3,648,184	0	0	0	0	0	0	0	0	0	62,013,625	-65,661,809	0	0	0	
23	Increase in reserves arising from the pre-bankruptcy settlement procedure	50	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
24	Balance on the last day of the current business year reporting period (ADP 31 to 50)	51	120,560,000	21,836,295	51,761,317	8,419,148	7,375,900	0	2,140,779	0	0	0	0	72,880	473,074,254	7,425,852	677,914,625	0	677,914,625	
APPENDIX TO THE STATEMENT OF CHANGES IN EQUITY (to be filled in by undertakings that draw up financial statements in accordance with the IFRS)																				
I.	OTHER COMPREHENSIVE INCOME FOR THE CURRENT PERIOD, NET OF TAX (ADP 33 to 41)	52	0	0	0	0	0	0	0	0	0	0	0	-627,096	0	0	-627,096	0	-627,096	
II.	COMPREHENSIVE INCOME OR LOSS FOR THE CURRENT PERIOD (ADP 32 do 52)	53	0	0	0	0	0	0	0	0	0	0	0	-627,096	0	7,425,852	6,798,756	0	6,798,756	
III.	TRANSACTIONS WITH OWNERS IN THE CURRENT PERIOD RECOGNISED DIRECTLY IN EQUITY (ADP 42 to 50)	54	0	0	3,648,184	-319,800	-319,800	0	0	0	0	0	0	0	51,244,408	-65,661,809	-10,769,217	0	-10,769,217	

NOTES TO FINANCIAL STATEMENTS (PFI)


(drawn up for semi-annual periods)

NAME OF THE ISSUER:	JGL D.D.
PERSONAL IDENTIFICATION NUMBER (OIB):	20950636972
REPORTING PERIOD:	1.1.2021. - 30.6.2021.

The notes to the financial statements for the semi-annual periods include the items below and are an integral part of the JGL Group's Semi-Annual Management Report for the first six months of 2021. The semi-annual report of the JGL Group management for the first six months of 2021 is available on the website of JGL d.d. <https://www.jgl.hr/o-nama/jgl-danas/financijski-izvjestaji>, and on the websites of the Zagreb Stock Exchange and HANFA. Items included:

- a. explanation of business events relevant to understanding changes in the statement of financial position and financial performance for the reporting semi-annual period of the issuer with respect to the last business year: information is provided regarding these events and relevant information published in the last annual financial statement is updated (items 15 to 15C IAS 34 - Interim financial reporting)
- b. information on the access to the latest annual financial statements, for the purpose of understanding information published in the notes to financial statements drawn up for the semi-annual reporting period
- c. a statement explaining that the same accounting policies are applied while drawing up financial statements for the semi-annual reporting period as in the latest annual financial statements or, in the case where the accounting policies have changed, a description of the nature and effect of the changes (item 16.A (a) IAS 34 - Interim financial reporting)
- d. a description of the financial performance in the case of the issuer whose business is seasonal (items 37 and 38 IAS 34 - Interim financial reporting)
- e. other comments prescribed by IAS 34 - Interim financial reporting
- f. in the notes to the semi-annual financial statements, in addition to the information stated above, information in respect of the following matters shall be disclosed:
 1. undertaking's name, registered office (address), legal form, country of establishment, entity's registration number and, if applicable, the indication whether the undertaking is undergoing liquidation, bankruptcy proceedings, shortened termination proceedings or extraordinary administration
 2. adopted accounting policies (only an indication of whether there has been a change from the previous period)
 3. the total amount of any financial commitments, guarantees or contingencies that are not included in the balance sheet, and an indication of the nature and form of any valuable security which has been provided; any commitments concerning pensions of the undertaking within the group or company linked by virtue of participating interest shall be disclosed separately

4. the amount and nature of individual items of income or expenditure which are of exceptional size or incidence
5. amounts owed by the undertaking and falling due after more than five years, as well as the total debts of the undertaking covered by valuable security furnished by the undertaking, specifying the type and form of security
6. average number of employees during the financial year
7. where, in accordance with the regulations, the undertaking capitalised on the cost of salaries in part or in full, information on the amount of the total cost of employees during the year broken down into the amount directly debiting the costs of the period and the amount capitalised on the value of the assets during the period, showing separately the total amount of net salaries and the amount of taxes, contributions from salaries and contributions on salaries
8. where a provision for deferred tax is recognised in the balance sheet, the deferred tax balances at the end of the financial year, and the movement in those balances during the financial year
9. the name and registered office of each of the undertakings in which the undertaking, either itself or through a person acting in their own name but on the undertaking's behalf, holds a participating interest, showing the proportion of the capital held, the amount of capital and reserves, and the profit or loss for the latest financial year of the undertaking concerned for which financial statements have been adopted; the information concerning capital and reserves and the profit or loss may be omitted where the undertaking concerned does not publish its balance sheet and is not controlled by another undertaking
10. the number and the nominal value or, in the absence of a nominal value, the accounting par value of the shares subscribed during the financial year within the limits of the authorised capital
11. the existence of any participation certificates, convertible debentures, warrants, options or similar securities or rights, with an indication of their number and the rights they confer
12. the name, registered office and legal form of each of the undertakings of which the undertaking is a member having unlimited liability
13. the name and registered office of the undertaking which draws up the consolidated financial statements of the largest group of undertakings of which the undertaking forms part as a controlled group member
14. the name and registered office of the undertaking which draws up the consolidated financial statements of the smallest group of undertakings of which the undertaking forms part as a controlled group member and which is also included in the group of undertakings referred to in point 13
15. the place where copies of the consolidated financial statements referred to in points 13 and 14 may be obtained, provided that they are available
16. the nature and business purpose of the undertaking's arrangements that are not included in the balance sheet and the financial impact on the undertaking of those arrangements, provided that the risks or benefits arising from such arrangements are material and in so far as the disclosure of such risks or benefits is necessary for the purposes of assessing the financial position of the undertaking
17. the nature and the financial effect of material events arising after the balance sheet date which are not reflected in the profit and loss account or balance sheet.



FINANCIAL STATEMENTS

JGL D.D.

BALANCE SHEET	56
STATEMENT OF PROFIT OR LOSS	60
STATEMENT OF CASH FLOWS – DIRECT METHOD	64
STATEMENT OF CHANGES IN EQUITY	66
NOTES ACCOMPANYING THE FINANCIAL STATEMENTS – PFI	68

BALANCE SHEET
balance as at 30.6.2021
in HRK

Submitter:
JGL D.D.

Item 1	ADP code 2	Last day of the preceding business year 3	At the reporting date of the current period 4
ASSETS			
A	RECEIVABLES FOR SUBSCRIBED CAPITAL UNPAID	001	
B	FIXED ASSETS (ADP 003+010+020+031+036)	002	675,386,055
I.	INTANGIBLE ASSETS (ADP 004 to 009)	003	87,344,789
	Research and development	004	20,988,460
	Concessions, patents, licences, trademarks, software and other rights	005	21,615,390
	Goodwill	006	0
	Advances for the purchase of intangible assets	007	0
	Intangible assets in preparation	008	39,106,726
	Other intangible assets	009	5,634,213
II.	TANGIBLE ASSETS (ADP 011 to 019)	010	558,238,496
	Land	011	44,679,855
	Buildings	012	228,238,410
	Plant and equipment	013	180,678,096
	Tools, working inventory and transportation assets	014	11,560,042
	Biological assets	015	0
	Advances for the purchase of tangible assets	016	0
	Tangible assets in preparation	017	74,400,937
	Other tangible assets	018	1,128,618
	Investment property	019	17,552,538
III.	FIXED FINANCIAL ASSETS (ADP 021 to 030)	020	139,871,633
	Investments in holdings (shares) of undertakings within the group	021	138,640,058
	Investments in other securities of undertakings within the group	022	0
	Loans, deposits, etc. to undertakings within the group	023	0
	Investments in holdings (shares) of companies linked by virtue of participating interests	024	49,000
	Investment in other securities of companies linked by virtue of participating interests	025	0
	Loans, deposits etc. to companies linked by virtue of participating interests	026	0
	Investments in securities	027	1,182,575
	Loans, deposits, etc. given	028	0
	Other investments accounted for using the equity method	029	0
	Other fixed financial assets	030	0
IV.	RECEIVABLES (ADP 032 to 035)	031	0
	Receivables from undertakings within the group	032	0
	Receivables from companies linked by virtue of participating interests	033	0

BALANCE SHEET
balance as at 30.6.2021
in HRK

Submitter:
JGL D.D.

Item 1	ADP code 2	Last day of the preceding business year 3	At the reporting date of the current period 4
Customer receivables	034	0	0
Other receivables	035	0	0
V. DEFERRED TAX ASSETS	036	16,908,336	16,908,336
C CURRENT ASSETS (ADP 038+046+053+063)	037	530,441,806	497,154,872
I. INVENTORIES (ADP 039 to 045)	038	170,709,733	222,864,676
Raw materials and consumables	039	63,077,273	81,175,303
Production in progress	040	3,550	404,577
Finished goods	041	69,431,612	96,512,856
Merchandise	042	38,132,914	44,771,940
Advances for inventories	043	64,384	0
Fixed assets held for sale	044	0	0
Biological assets	045	0	0
II. RECEIVABLES (ADP 047 to 052)	046	325,884,486	262,381,562
Receivables from undertakings within the group	047	167,657,110	136,763,166
Receivables from companies linked by virtue of participating interests	048	0	0
Customer receivables	049	130,307,016	93,815,067
Receivables from employees and members of the undertaking	050	6,279	81,360
Receivables from government and other institutions	051	4,715,173	2,561,122
Other receivables	052	23,198,908	29,160,847
III. CURRENT FINANCIAL ASSETS (ADP 054 to 062)	053	21,970,056	5,243,870
Investments in holdings (shares) of undertakings within the group	054	0	0
Investments in other securities of undertakings within the group	055	0	0
Loans, deposits, etc. to undertakings within the group	056	2,261,070	5,243,870
Investments in holdings (shares) of companies linked by virtue of participating interests	057	0	0
Investment in other securities of companies linked by virtue of participating interests	058	0	0
Loans, deposits etc. to companies linked by virtue of participating interests	059	0	0
Investments in securities	060	0	0
Loans, deposits, etc. given	061	0	0
Other financial assets	062	19,708,986	0
IV. CASH AT BANK AND IN HAND	063	11,877,531	6,664,764
D PREPAID EXPENSES AND ACCRUED INCOME	064	3,010,046	1,954,793
E TOTAL ASSETS (ADP 001+002+037+064)	065	1,208,837,907	1,301,472,919
F OFF-BALANCE SHEET ITEMS	066	66,669,661	114,435,590

BALANCE SHEET
balance as at 30.6.2021
in HRK

Submitter:
JGL D.D.

Item 1	ADP code 2	Last day of the preceding business year 3	At the reporting date of the current period 4	
LIABILITIES				
A	CAPITAL AND RESERVES (AOP 068 do 070+076+077+083+086+089)	067	690,828,759	754,935,080
I.	INITIAL (SUBSCRIBED) CAPITAL	068	120,560,000	120,560,000
II.	CAPITAL RESERVES	069	21,836,295	21,836,295
III.	RESERVES FROM PROFIT (AOP 071+072-073+074+075)	070	51,297,160	54,945,344
	1 Legal reserves	071	48,113,133	51,761,317
	2 Reserves for treasury shares	072	8,738,948	8,419,148
	3 Treasury shares and holdings (deductible item)	073	-7,695,700	-7,375,900
	4 Statutory reserves	074	0	0
	5 Other reserves	075	2,140,779	2,140,779
IV.	REVALUATION RESERVES	076	0	0
V.	FAIR VALUE RESERVES AND OTHER (AOP 078 do 082)	077	0	0
	1 Financial assets at fair value through other comprehensive income (i.e. available for sale)	078	0	0
	2 Cash flow hedge - effective portion	079	0	0
	3 Hedge of a net investment in a foreign operation - effective portion	080	0	0
	4 Other fair value reserves	081	0	0
	5 Exchange differences arising from the translation of foreign operations (consolidation)	082	0	0
VI.	RETAINED PROFIT OR LOSS BROUGHT FORWARD (ADP 084-085)	083	431,029,259	482,815,653
	1 Retained profit	084	431,029,259	482,815,653
	2 Loss brought forward	085	0	0
VII.	PROFIT OR LOSS FOR THE BUSINESS YEAR (ADP 087-088)	086	66,106,045	74,777,788
	1 Profit for the business year	087	66,106,045	74,777,788
	2 Loss for the business year	088	0	0
VIII.	MINORITY (NON-CONTROLLING) INTEREST	089	0	0
B	PROVISIONS (ADP 091 to 096)	090	2,815,556	2,815,556
	1 Provisions for pensions, termination benefits and similar obligations	091	1,990,335	1,990,335
	2 Provisions for tax liabilities	092	0	0
	3 Provisions for ongoing legal cases	093	825,221	825,221
	4 Provisions for renewal of natural resources	094	0	0
	5 Provisions for warranty obligations	095	0	0
	6 Other provisions	096	0	0

BALANCE SHEET
balance as at 30.6.2021
in HRK

Submitter:
JGL D.D.

Item 1	ADP code 2	Last day of the preceding business year 3	At the reporting date of the current period 4
C LONG-TERM LIABILITIES (ADP 098 to 108)	097	325,807,253	371,565,981
1 Liabilities to undertakings within the group	098	0	0
2 Liabilities for loans, deposits, etc. of undertakings within the group	099	0	0
3 Liabilities to companies linked by virtue of participating interests	100	0	0
4 Liabilities for loans, deposits etc. of companies linked by virtue of participating interests	101	0	0
5 Liabilities for loans, deposits etc.	102	0	0
6 Liabilities to banks and other financial institutions	103	197,522,684	243,065,011
7 Liabilities for advance payments	104	0	0
8 Liabilities to suppliers	105	0	0
9 Liabilities for securities	106	128,284,569	128,500,970
10 Other long-term liabilities	107	0	0
11 Deferred tax liability	108	0	0
D SHORT-TERM LIABILITIES (ADP 110 to 123)	109	180,973,194	165,541,763
1 Liabilities to undertakings within the group	110	800,326	4,373,915
2 Liabilities for loans, deposits, etc. of undertakings within the group	111	0	0
3 Liabilities to companies linked by virtue of participating interests	112	0	0
4 Liabilities for loans, deposits etc. of companies linked by virtue of participating interests	113	0	0
5 Liabilities for loans, deposits etc.	114	0	0
6 Liabilities to banks and other financial institutions	115	42,952,053	22,079,672
7 Liabilities for advance payments	116	2,374,792	3,359,455
8 Liabilities to suppliers	117	103,535,370	119,442,137
9 Liabilities for securities	118	4,000,000	6,000,000
10 Liabilities to employees	119	13,922,259	4,851,253
11 Taxes, contributions and similar liabilities	120	12,093,808	2,767,750
12 Liabilities arising from the share in the result	121	20,100	193,900
13 Liabilities arising from fixed assets held for sale	122	0	
14 Other short-term liabilities	123	1,274,486	2,473,681
E ACCRUALS AND DEFERRED INCOME	124	8,413,145	6,614,539
F TOTAL – LIABILITIES (ADP 067+090+097+109+124)	125	1,208,837,907	1,301,472,919
G OFF-BALANCE SHEET ITEMS	126	66,669,661	114,435,590

STATEMENT OF PROFIT OR LOSS
for the period 1.1.2021 to 30.6.2021
in HRK

Submitter:
JGL D.D.

Item	ADP code	Same period of the previous year	Current period
1	2	3	4
I. OPERATING INCOME (ADP 002 to 006)	001	276,487,320	289,532,005
1 Income from sales with undertakings within the group	002	75,901,274	64,062,119
2 Income from sales (outside group)	003	196,461,769	158,720,465
3 Income from the use of own products, goods and services	004	0	0
4 Other operating income with undertakings within the group	005	912,378	64,968,239
5 Other operating income (outside the group)	006	3,211,899	1,781,182
II. OPERATING EXPENSES (ADP 08+009+013+017+018+019+022+029)	007	219,661,719	214,097,383
1 Changes in inventories of work in progress and finished goods	008	-17,726,156	-30,870,401
2 Material costs (ADP 010 to 012)	009	148,968,921	154,177,913
a) Costs of raw materials and consumables	010	93,848,951	89,875,363
b) Costs of goods sold	011	19,318,173	25,582,131
c) Other external costs	012	35,801,797	38,720,419
3 Staff costs (ADP 014 to 016)	013	47,071,464	50,756,573
a) Net salaries and wages	014	29,464,522	31,695,503
b) Tax and contributions from salary costs	015	11,715,185	12,521,953
c) Contributions on salaries	016	5,891,757	6,539,117
4 Depreciation	017	19,132,893	19,835,684
5 Other costs	018	10,115,503	14,018,210
6 Value adjustments (ADP 020+021)	019	0	0
a) fixed assets other than financial assets	020	0	0
b) current assets other than financial assets	021	0	0
7 Provisions (ADP 023 to 028)	022	0	0
a) Provisions for pensions, termination benefits and similar obligations	023	0	0
b) Provisions for tax liabilities	024	0	0
c) Provisions for ongoing legal cases	025	0	0
d) Provisions for renewal of natural resources	026	0	0
e) Provisions for warranty obligations	027	0	0
f) Other provisions	028	0	0
8 Other operating expenses	029	12,099,094	6,179,404
III. FINANCIAL INCOME (ADP 031 to 040)	030	7,629,575	5,232,461
1 Income from investments in holdings (shares) of undertakings within the group	031	0	0
2 Income from investments in holdings (shares) of companies linked by virtue of participating interests	032	0	0

STATEMENT OF PROFIT OR LOSS
for the period 1.1.2021 to 30.6.2021
in HRK

Submitter:
JGL D.D.

Item	ADP code	Same period of the previous year	Current period
1	2	3	4
3 Income from other long-term financial investment and loans granted to undertakings within the group	033	0	0
4 Other interest income from operations with undertakings within the group	034	533,056	0
5 Exchange rate differences and other financial income from operations with undertakings within the group	035	2,593,398	3,936,640
6 Income from other long-term financial investments and loans	036	0	0
7 Other interest income	037	561	4,154
8 Exchange rate differences and other financial income	038	4,451,314	1,265,845
9 Unrealised gains (income) from financial assets	039	0	0
10 Other financial income	040	51,246	25,822
IV. FINANCIAL EXPENSES (ADP 042 to 048)	041	25,886,744	5,889,295
1 Interest expenses and similar expenses with undertakings within the group	042	0	0
2 Exchange rate differences and other expenses from operations with undertakings within the group	043	14,145,956	0
3 Interest expenses and similar expenses	044	6,486,321	4,368,569
4 Exchange rate differences and other expenses	045	3,496,705	1,520,726
5 Unrealised losses (expenses) from financial assets	046	1,757,762	0
6 Value adjustments of financial assets (net)	047	0	0
7 Other financial expenses	048	0	0
V. SHARE IN PROFIT FROM UNDERTAKINGS LINKED BY VIRTUE OF PARTICIPATING INTERESTS	049	0	0
VI. SHARE IN PROFIT FROM JOINT VENTURES	050	0	0
VII. SHARE IN LOSS OF COMPANIES LINKED BY VIRTUE OF PARTICIPATING INTEREST	051	0	0
VIII. SHARE IN LOSS OF JOINT VENTURES	052	0	0
IX. TOTAL INCOME (ADP 001+030+049 +050)	053	284,116,895	294,764,466
X. TOTAL EXPENDITURE (ADP 007+041+051 + 052)	054	245,548,463	219,986,678
XI. PRE-TAX PROFIT OR LOSS (ADP 053-054)	055	38,568,432	74,777,788
1 Pre-tax profit (ADP 053-054)	056	38,568,432	74,777,788
2 Pre-tax loss (ADP 054-053)	057	0	0
XII. INCOME TAX	058	0	0
XIII. PROFIT OR LOSS FOR THE PERIOD (ADP 055-059)	059	38,568,432	74,777,788
1 Profit for the period (ADP 055-059)	060	38,568,432	74,777,788
2 Loss for the period (ADP 059-055)	061	0	0

STATEMENT OF PROFIT OR LOSS
for the period 1.1.2021 to 30.6.2021
in HRK

Submitter:
JGL D.D.

Item	ADP code	Same period of the previous year	Current period
1	2	3	4
DISCONTINUED OPERATIONS (to be filled in by undertakings subject to IFRS only with discontinued operations)			
XIV. PRE-TAX PROFIT OR LOSS OF DISCONTINUED OPERATIONS (ADP 063-064)	062	0	0
1 Pre-tax profit from discontinued operations	063	0	0
2 Pre-tax loss on discontinued operations	064	0	0
XV. INCOME TAX OF DISCONTINUED OPERATIONS	065	0	0
1 Discontinued operations profit for the period (ADP 062-065)	066	0	0
2 Discontinued operations loss for the period (ADP 065-062)	067	0	0
TOTAL OPERATIONS (to be filled in only by undertakings subject to IFRS with discontinued operations)			
XVI. PRE-TAX PROFIT OR LOSS (ADP 055-+062)	068	0	0
1 Pre-tax profit (ADP 068)	069	0	0
2 Pre-tax loss (ADP 068)	070	0	0
XVII. INCOME TAX (ADP 058+065)	071	0	0
XVIII. PROFIT OR LOSS FOR THE PERIOD (ADP 068-071)	072	0	0
1 Profit for the period (ADP 068-071)	073	0	0
2 Loss for the period (ADP 071-068)	074	0	0
APPENDIX to the P&L (to be filled in by undertakings that draw up consolidated annual financial statements)			
XIX. PROFIT OR LOSS FOR THE PERIOD (ADP 076+077)	075	0	0
1 Attributable to owners of the parent	076	0	0
2 Attributable to minority (non-controlling) interest	077	0	0
STATEMENT OF OTHER COMPREHENSIVE INCOME (to be filled in by undertakings subject to IFRS)			
I. PROFIT OR LOSS FOR THE PERIOD	078	38,568,432	74,777,788
II. OTHER COMPREHENSIVE INCOME/LOSS BEFORE TAX (ADP 80+ 87)	079	0	0
III. Items that will not be reclassified to profit or loss (ADP 081 to 085)	080	0	0
1 Changes in revaluation reserves of fixed tangible and intangible assets	081	0	0
2 Gains or losses from subsequent measurement of equity instruments at fair value through other comprehensive income	082	0	0

STATEMENT OF PROFIT OR LOSS
for the period 1.1.2021 to 30.6.2021
in HRK

Submitter:
JGL D.D.

Item 1	ADP code 2	Same period of the previous year 3	Current period 4
3 Fair value changes of financial liabilities at fair value through statement of profit or loss, attributable to changes in their credit risk	083	0	0
4 Actuarial gains/losses on the defined benefit obligation	084	0	0
5 Other items that will not be reclassified	085	0	0
6 Income tax relating to items that will not be reclassified	086	0	0
IV. Items that may be reclassified to profit or loss (ADP 088 to 095)	087	0	0
1 Exchange rate differences from translation of foreign operations	088	0	0
2 Gains or losses from subsequent measurement of debt securities at fair value through other comprehensive income	089	0	0
3 Profit or loss arising from effective cash flow hedging	090	0	0
4 Profit or loss arising from effective hedge of a net investment in a foreign operation	091	0	0
5 Share in other comprehensive income/loss of companies linked by virtue of participating interests	092	0	0
6 Changes in fair value of the time value of option	093	0	0
7 Changes in fair value of forward elements of forward contracts	094	0	0
8 Other items that may be reclassified to profit or loss	095	0	0
9 Income tax relating to items that may be reclassified to profit or loss	096	0	0
V. NET OTHER COMPREHENSIVE INCOME OR LOSS (ADP 080+087- 086 - 096)	097	0	0
VI. COMPREHENSIVE INCOME OR LOSS FOR THE PERIOD (ADP 078+097)	098	38,568,432	74,777,788
APPENDIX to the Statement on comprehensive income (to be filled in by undertakings that draw up consolidated statements)			
VI. VI COMPREHENSIVE INCOME OR LOSS FOR THE PERIOD (ADP 100+101)	099	0	0
1 Attributable to owners of the parent	100	0	0
2 Attributable to minority (non-controlling) interest	101	0	0

STATEMENT OF CASH FLOWS - DIRECT METHOD
for the period 1.1.2021 to 30.6.2021
in HRK


Submitter:
JGL D.D.

Item	ADP code	Same period of the previous year	Current period
1	2	3	4
Cash flow from operating activities			
1 Cash receipts from customers	001	309,873,684	301,111,276
2 Cash receipts from royalties, fees, commissions and other revenue	002	0	0
3 Cash receipts from insurance premiums	003	251,032	286,228
4 Cash receipts from tax refund	004	6,898,134	6,990,179
5 Other cash receipts from operating activities	005	881,324	411,027
I. Total cash receipts from operating activities (ADP 001 to 005)	006	317,904,174	308,798,710
1 Cash payments to suppliers	007	-183,659,219	-208,575,740
2 Cash payments to employees	008	-38,871,124	-46,753,305
3 Cash payments for insurance premiums	009	-884,323	-1,050,550
4 Interest paid	010	-6,187,502	-3,409,552
5 Income tax paid	011	-64,802	-254,895
6 Other cash payments from operating activities	012	-31,488,855	-30,399,113
II. Total cash payments from operating activities (ADP 007 to 012)	013	-261,155,825	-290,443,155
A NET CASH FLOW FROM OPERATING ACTIVITIES (ADP 006 + 013)	014	56,748,349	18,355,555
Cash flow from investment activities			
1 Cash receipts from sales of fixed tangible and intangible assets	015	201,984	971,657
2 Cash receipts from sales of financial instruments	016	0	19,411,346
3 Interest received	017	42,233	110
4 Dividends received	018	0	0
5 Cash receipts from the repayment of loans and deposits	019	5,288,100	0
6 Other cash receipts from investment activities	020	0	0
III. Total cash receipts from investment activities (ADP 015 to 020)	021	5,532,317	20,383,113
1 Cash payments for the purchase of fixed tangible and intangible assets	022	-12,933,236	-48,434,922
2 Cash payments for the acquisition of financial instruments	023	-44,575,176	0
3 Cash payments for loans and deposits	024	-183,379	-3,028,306
4 Acquisition of a subsidiary, net of cash acquired	025	0	-20,000
5 Other cash payments from investment activities	026	0	0
IV. Total cash payments from investment activities (ADP 022 to 026)	027	-57,691,791	-51,483,228
B NET CASH FLOW FROM INVESTMENT ACTIVITIES (ADP 021 + 027)	028	-52,159,474	-31,100,115
Cash flow from financing activities			
1 Cash receipts from the increase in initial (subscribed) capital	029	0	0
2 Cash receipts the from issue of equity financial instruments and debt financial instruments	030	0	0
3 Cash receipts from credit principals, loans and other borrowings	031	0	40,485,485
4 Other cash receipts from financing activities	032	70,000	0

STATEMENT OF CASH FLOWS - DIRECT METHOD
for the period 1.1.2021 to 30.6.2021
in HRK

Submitter:
JGL D.D.

Item	ADP code	Same period of the previous year	Current period
1	2	3	4
V. Total cash receipts from financing activities (ADP 029 to 032)	033	70,000	40,485,485
1 Cash payments for the repayment of credit principals, loans and other borrowings and debt financial instruments	034	-13,334,393	-13,294,337
2 Cash payments for dividends	035	-10,052,937	-12,277,551
3 Cash payments for finance lease	036	-9,933,080	-7,589,580
4 Cash payments for the redemption of own shares and decrease in initial (subscribed) capital	037	-206,700	-60,400
5 Other cash payments from financing activities	038	-70,000	0
VI. Total cash payments from financing activities (ADP 034 to 038)	039	-33,597,110	-33,221,868
C NET CASH FLOW FROM FINANCING ACTIVITIES (ADP 033 +039)	040	-33,527,110	7,263,617
1 Unrealised exchange rate differences in respect of cash and cash equivalents	041	1,327,715	268,176
D NET INCREASE OR DECREASE IN CASH FLOWS (ADP 014 + 028 + 040 + 041)	042	-27,610,520	-5,212,767
E CASH AND CASH EQUIVALENTS AT THE BEGINNING OF THE PERIOD	043	57,446,615	11,877,531
F CASH AND CASH EQUIVALENTS AT THE END OF THE PERIOD (ADP 042+043)	044	29,836,095	6,664,764



STATEMENT OF CHANGES IN EQUITY
for the period 1.1.2021 to 30.6.2021
in HRK

Submitter:
JGL D.D.

Item	ADP code	ATTRIBUTABLE TO OWNERS OF THE PARENT																	Minority (non-controlling) interest	Total capital and reserves
		Initial (subscribed) capital	Capital reserves	Legal reserves	Reserves for treasury shares	Treasury shares and holdings (deductible item)	Statutory reserves	Other reserves	Revaluation reserves	Fair value of financial assets through other comprehensive income (available for sale)	Cash flow hedge - effective portion	Hedge of a net investment in a foreign operation - effective portion	Other fair value reserves	Exchange rate differences from translation of foreign operations	Retained profit / loss brought forward	Profit/loss for the business year	Total attributable to owners of the parent			
1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18 (3 do 6 - 7 + 8 do 17)	19	20 (18+19)	
PREVIOUS PERIOD																				
1		Balance on the first day of the previous business year	01	119,255,000	16,720,695	42,107,648	8,316,947	7,273,700	0	2,140,779	0	0	0	0	0	371,724,631	77,876,691	630,868,691	0	630,868,691
2		Changes in accounting policies	02	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
3		Correction of errors	03	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
4		Balance on the first day of the previous business year (restated) (ADP 01 to 03)	04	119,255,000	16,720,695	42,107,648	8,316,947	7,273,700	0	2,140,779	0	0	0	0	0	371,724,631	77,876,691	630,868,691	0	630,868,691
5		Profit/loss of the period	05	0	0	0	0	0	0	0	0	0	0	0	0	0	38,568,432	38,568,432	0	38,568,432
6		Exchange rate differences from translation of foreign operations	06	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
7		Changes in revaluation reserves of fixed tangible and intangible assets	07	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
8		Gains or losses from subsequent measurement of financial assets at fair value through other comprehensive income (available for sale)	08	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
9		Profit or loss arising from effective cash flow hedge	09	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
10		Profit or loss arising from effective hedge of a net investment in a foreign operation	10	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
11		Share in other comprehensive income/loss of companies linked by virtue of participating interests	11	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
12		Actuarial gains/losses on the defined benefit obligation	12	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
13		Other changes in equity unrelated to owners	13	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
14		Tax on transactions recognised directly in equity	14	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
15		Decrease in initial (subscribed) capital (other than arising from the pre-bankruptcy settlement procedure or from the reinvestment of profit)	15	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
16		Decrease in initial (subscribed) capital arising from the pre-bankruptcy settlement procedure	16	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
17		Decrease in initial (subscribed) capital arising from the reinvestment of profit	17	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
18		Redemption of treasury shares/holdings	18	0	0	0	-163,000	-163,000	0	0	0	0	0	0	0	792,060	0	792,060	0	792,060
19		Payments from members/shareholders	19	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
20		Payment of share in profit/dividend	20	0	0	0	0	0	0	0	0	0	0	0	-10,094,337	0	-10,094,337	0	-10,094,337	
21		Other distributions and payments to members/shareholders	21	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
22		Transfer to reserves according to the annual schedule	22	0	0	6,005,485	0	0	0	0	0	0	0	0	71,871,206	-77,876,691	0	0	0	
23		Increase in reserves arising from the pre-bankruptcy settlement procedure	23	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
24		Balance on the last day of the previous business year reporting period (ADP 04 to 23)	24	119,255,000	16,720,695	48,113,133	8,153,947	7,110,700	0	2,140,779	0	0	0	0	0	434,293,560	38,568,432	660,134,846	0	660,134,846
APPENDIX TO THE STATEMENT OF CHANGES IN EQUITY (to be filled in by undertakings that draw up financial statements in accordance with the IFRS)																				
I.		OTHER COMPREHENSIVE INCOME OF THE PREVIOUS PERIOD, NET OF TA (ADP 06 to 14)	25	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
II.		COMPREHENSIVE INCOME OR LOSS FOR THE PREVIOUS PERIOD (ADP 05+25)	26	0	0	0	0	0	0	0	0	0	0	0	0	38,568,432	38,568,432	0	38,568,432	
III.		TRANSACTIONS WITH OWNERS IN THE PREVIOUS PERIOD RECOGNISED DIRECTLY IN EQUITY (ADP 15 to 23)	27	0	0	6,005,485	-163,000	-163,000	0	0	0	0	0	0	0	62,568,929	-77,876,691	-9,302,277	0	-9,302,277

STATEMENT OF CHANGES IN EQUITY
for the period 1.1.2021 to 30.6.2021
in HRK

Submitter:
JGL D.D.

Item	ADP code	ATTRIBUTABLE TO OWNERS OF THE PARENT																	Minority (non-controlling) interest	Total capital and reserves
		Initial (subscribed) capital	Capital reserves	Legal reserves	Reserves for treasury shares	Treasury shares and holdings (deductible item)	Statutory reserves	Other reserves	Revaluation reserves	Fair value of financial assets through other comprehensive income (available for sale)	Cash flow hedge - effective portion	Hedge of a net investment in a foreign operation - effective portion	Other fair value reserves	Exchange rate differences from translation of foreign operations	Retained profit / loss brought forward	Profit/loss for the business year	Total attributable to owners of the parent			
1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18 (3 do 6 - 7 + 8 do 17)	19	20 (18+19)	
CURRENT PERIOD																				
1		28	120,560,000	21,836,295	48,113,133	8,738,948	7,695,700	0	0	2,140,779	0	0	0	0	0	431,029,259	66,106,045	690,828,759	0	690,828,759
2	Changes in accounting policies	29	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
3	Correction of errors	30	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
4	Balance on the first day of the current business year (restated) (AOP 28 to 30)	31	120,560,000	21,836,295	48,113,133	8,738,948	7,695,700	0	0	2,140,779	0	0	0	0	0	431,029,259	66,106,045	690,828,759	0	690,828,759
5	Profit/loss of the period	32	0	0	0	0	0	0	0	0	0	0	0	0	0	0	74,777,788	74,777,788	0	74,777,788
6	Exchange rate differences from translation of foreign operations	33	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
7	Changes in revaluation reserves of fixed tangible and intangible assets	34	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
8	Gains or losses from subsequent measurement of financial assets at fair value through other comprehensive income (available for sale)	35	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
9	Profit or loss arising from effective cash flow hedge	36	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
10	Profit or loss arising from effective hedge of a net investment in a foreign operation	37	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
11	Share in other comprehensive income/loss of companies linked by virtue of participating interests	38	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
12	Actuarial gains/losses on the defined benefit obligation	39	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
13	Other changes in equity unrelated to owners	40	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
14	Tax on transactions recognised directly in equity	41	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
15	Decrease in initial (subscribed) capital (other than arising from the pre-bankruptcy settlement procedure or from the reinvestment of profit)	42	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
16	Decrease in initial (subscribed) capital arising from the pre-bankruptcy settlement procedure	43	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
17	Decrease in initial (subscribed) capital arising from the reinvestment of profit	44	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
18	Redemption of treasury shares/holdings	45	0	0	0	-319,800	-319,800	0	0	0	0	0	0	0	0	1,779,884	0	1,779,884	0	1,779,884
19	Payments from members/shareholders	46	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
20	Payment of share in profit/dividend	47	0	0	0	0	0	0	0	0	0	0	0	0	-12,451,351	0	-12,451,351	0	-12,451,351	
21	Other distributions and payments to members/shareholders	48	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
22	Carryforward per annual plan	49	0	0	3,648,184	0	0	0	0	0	0	0	0	0	62,457,861	-66,106,045	0	0	0	0
23	Increase in reserves arising from the pre-bankruptcy settlement procedure	50	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
24	Balance on the last day of the current business year reporting period (ADP 31 to 50)	51	120,560,000	21,836,295	51,761,317	8,419,148	7,375,900	0	0	2,140,779	0	0	0	0	0	482,815,653	74,777,788	754,935,080	0	754,935,080
APPENDIX TO THE STATEMENT OF CHANGES IN EQUITY (to be filled in by undertakings that draw up financial statements in accordance with the IFRS)																				
I.	OTHER COMPREHENSIVE INCOME FOR THE CURRENT PERIOD, NET OF TAX (ADP 33 to 41)	52	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
II.	COMPREHENSIVE INCOME OR LOSS FOR THE CURRENT PERIOD (ADP 32 do 52)	53	0	0	0	0	0	0	0	0	0	0	0	0	0	0	74,777,788	74,777,788	0	74,777,788
III.	TRANSACTIONS WITH OWNERS IN THE CURRENT PERIOD RECOGNISED DIRECTLY IN EQUITY (ADP 42 to 50)	54	0	0	3,648,184	-319,800	-319,800	0	0	0	0	0	0	0	0	51,786,394	-66,106,045	-10,671,467	0	-10,671,467

NOTES TO FINANCIAL STATEMENTS (PFI)

(drawn up for semi-annual periods)

NAME OF THE ISSUER:	JGL D.D.
PERSONAL IDENTIFICATION NUMBER (OIB):	20950636972
REPORTING PERIOD:	1.1.2021. - 30.6.2021.

The notes to the financial statements for the semi-annual periods include the items below and are an integral part of the JGL Group's Semi-Annual Management Report for the first six months of 2021. The semi-annual report of the JGL Group management for the first six months of 2021 is available on the website of JGL d.d. <https://www.jgl.hr/o-nama/jgl-danas/financijski-izvjestaji>, and on the websites of the Zagreb Stock Exchange and HANFA. Items included:

- a. explanation of business events relevant to understanding changes in the statement of financial position and financial performance for the reporting semi-annual period of the issuer with respect to the last business year: information is provided regarding these events and relevant information published in the last annual financial statement is updated (items 15 to 15C IAS 34 - Interim financial reporting)
- b. information on the access to the latest annual financial statements, for the purpose of understanding information published in the notes to financial statements drawn up for the semi-annual reporting period
- c. a statement explaining that the same accounting policies are applied while drawing up financial statements for the semi-annual reporting period as in the latest annual financial statements or, in the case where the accounting policies have changed, a description of the nature and effect of the changes (item 16.A (a) IAS 34 - Interim financial reporting)
- d. a description of the financial performance in the case of the issuer whose business is seasonal (items 37 and 38 IAS 34 - Interim financial reporting)
- e. other comments prescribed by IAS 34 - Interim financial reporting
- f. in the notes to the semi-annual financial statements, in addition to the information stated above, information in respect of the following matters shall be disclosed:
 1. undertaking's name, registered office (address), legal form, country of establishment, entity's registration number and, if applicable, the indication whether the undertaking is undergoing liquidation, bankruptcy proceedings, shortened termination proceedings or extraordinary administration
 2. adopted accounting policies (only an indication of whether there has been a change from the previous period)
 3. the total amount of any financial commitments, guarantees or contingencies that are not included in the balance sheet, and an indication of the nature and form of any valuable security which has been provided; any commitments concerning pensions of the undertaking within the group or company linked by virtue of participating interest shall be disclosed separately

4. the amount and nature of individual items of income or expenditure which are of exceptional size or incidence
5. amounts owed by the undertaking and falling due after more than five years, as well as the total debts of the undertaking covered by valuable security furnished by the undertaking, specifying the type and form of security
6. average number of employees during the financial year
7. where, in accordance with the regulations, the undertaking capitalised on the cost of salaries in part or in full, information on the amount of the total cost of employees during the year broken down into the amount directly debiting the costs of the period and the amount capitalised on the value of the assets during the period, showing separately the total amount of net salaries and the amount of taxes, contributions from salaries and contributions on salaries
8. where a provision for deferred tax is recognised in the balance sheet, the deferred tax balances at the end of the financial year, and the movement in those balances during the financial year
9. the name and registered office of each of the undertakings in which the undertaking, either itself or through a person acting in their own name but on the undertaking's behalf, holds a participating interest, showing the proportion of the capital held, the amount of capital and reserves, and the profit or loss for the latest financial year of the undertaking concerned for which financial statements have been adopted; the information concerning capital and reserves and the profit or loss may be omitted where the undertaking concerned does not publish its balance sheet and is not controlled by another undertaking
10. the number and the nominal value or, in the absence of a nominal value, the accounting par value of the shares subscribed during the financial year within the limits of the authorised capital
11. the existence of any participation certificates, convertible debentures, warrants, options or similar securities or rights, with an indication of their number and the rights they confer
12. the name, registered office and legal form of each of the undertakings of which the undertaking is a member having unlimited liability
13. the name and registered office of the undertaking which draws up the consolidated financial statements of the largest group of undertakings of which the undertaking forms part as a controlled group member
14. the name and registered office of the undertaking which draws up the consolidated financial statements of the smallest group of undertakings of which the undertaking forms part as a controlled group member and which is also included in the group of undertakings referred to in point 13
15. the place where copies of the consolidated financial statements referred to in points 13 and 14 may be obtained, provided that they are available
16. the nature and business purpose of the undertaking's arrangements that are not included in the balance sheet and the financial impact on the undertaking of those arrangements, provided that the risks or benefits arising from such arrangements are material and in so far as the disclosure of such risks or benefits is necessary for the purposes of assessing the financial position of the undertaking
17. the nature and the financial effect of material events arising after the balance sheet date which are not reflected in the profit and loss account or balance sheet.

STATEMENT OF RESPONSIBILITY OF THE CEO

According to the Accounting Act, the CEO is responsible for the preparation of consolidated and unconsolidated financial statements that provide a true and fair view of the Group's and the Company's financial positions and business performance in accordance with the applied accounting policies, and for maintaining adequate accounting records that enable the preparation of such financial statements at any moment. The CEO has a general responsibility to undertake steps that would, to a reasonable extent, enable the protection of the Group's and the Company's assets and the discovery and prevention of fraud or other irregularities.

The CEO is responsible for selecting appropriate accounting policies in accordance with the applied accounting standards that should be applied consistently, for making reasonable and careful judgements and estimates, and for preparing financial statements in accordance with the going concern principle, unless the assumption that the Group or the Company will continue to operate is inappropriate.

The CEO has a reasonable expectation that the Group and the Company have the appropriate resources to continue operating in the foreseeable future.

These statements represent consolidated statements of the Group and separate unconsolidated statements of the Company. The consolidated and the unconsolidated financial statements were approved by the CEO on 25 August 2021, as confirmed by his signature.



For JGL d.d.



Mislav Vučić
Executive Director